CA2283299A1 - 186 human secreted proteins - Google Patents

186 human secreted proteins Download PDF

Info

Publication number
CA2283299A1
CA2283299A1 CA 2283299 CA2283299A CA2283299A1 CA 2283299 A1 CA2283299 A1 CA 2283299A1 CA 2283299 CA2283299 CA 2283299 CA 2283299 A CA2283299 A CA 2283299A CA 2283299 A1 CA2283299 A1 CA 2283299A1
Authority
CA
Canada
Prior art keywords
gene
tissues
polypeptides
useful
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2283299
Other languages
French (fr)
Inventor
Steven M. Ruben
Craig A. Rosen
Carrie L. Fischer
Daniel R. Soppet
Kenneth C. Carter
Daniel P. Bednarik
Gregory A. Endress
Guo-Liang Yu
Jian Ni
Ping Feng
Paul E. Young
John M. Greene
Ann M. Ferrie
Roxanne Duan
Jing-Shan Hu
Kimberly A. Florence
Henrik S. Olsen
Reinhard Ebner
Laurie A. Brewer
Paul A. Moore
Yanggu Shi
David W. Lafleur
Yi Li
Zhizhen Zeng
Hla Kyaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences, Inc.
Steven M. Ruben
Craig A. Rosen
Carrie L. Fischer
Daniel R. Soppet
Kenneth C. Carter
Daniel P. Bednarik
Gregory A. Endress
Guo-Liang Yu
Jian Ni
Ping Feng
Paul E. Young
John M. Greene
Ann M. Ferrie
Roxanne Duan
Jing-Shan Hu
Kimberly A. Florence
Henrik S. Olsen
Reinhard Ebner
Laurie A. Brewer
Paul A. Moore
Yanggu Shi
David W. Lafleur
Yi Li
Zhizhen Zeng
Hla Kyaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc., Steven M. Ruben, Craig A. Rosen, Carrie L. Fischer, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Reinhard Ebner, Laurie A. Brewer, Paul A. Moore, Yanggu Shi, David W. Lafleur, Yi Li, Zhizhen Zeng, Hla Kyaw filed Critical Human Genome Sciences, Inc.
Publication of CA2283299A1 publication Critical patent/CA2283299A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The present invention relates to 186 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Description

s DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART~E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS DUN TOME.
CECI EST LE TOME ~ DE
NOTE: Pour !es tomes additionels, veuillez contacter !e Bureau canadien des brevets JUMBO APPLICATIONSIPATENTS
THIS SECT10N OF THE APP~ICATION/PATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME ~_ OF
NOTE: For additional vo~umes.pi~ase~contact the Canadian Patent Office' . ,-_ ____.~r_ .~...,___ _. _~.~.~..

186 Human Secreted Proteins Field of the Invention This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.
Background of the Invention Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.
One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.
Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles {or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.
Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.
2 Summary of the Invention The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides.
Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.
l0 Detailed Description Definitions The following definitions are provided to facilitate understanding of certain terms used throughout this specification.
In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
As used herein , a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
In the present invention, the full length sequence identified as SEQ ID NO:X
was often generated by overlapping sequences contained in multiple clones (contig T r analysis). A representative clone containing all or most of the sequence for SEQ ID
NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table l, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 12301 Park Lawn Drive, Rockville, Maryland 20852, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.
A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA contained within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, Sx SSC (750 mM NaCI, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), Sx Denhardt's solution, 10% dextran sulfate, and 20 ~tg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.
Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.
Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCI; 0.2M NaH2P04; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA;
followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. SX SSC).
Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA
or modified RNA or DNA. For example, polynucleotides can be composed of single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single-and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA
and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.
The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art.
Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, r ._ T _w.._...._ formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI
anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins 5 such as arginylation, and ubiquitination. (See, for instance, PROTEINS -STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W.
H. Freeman and Company, New York (1993); POSTTRANSLATIONAL
COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990);
Rattan et al., Ann NY Acad Sci 663:48-62 ( 1992).) "SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y"
refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.
"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.) Polynucleotides and Polyp~tides of the Invention FEATURES OF PROTEIN ENCODED BY GENE NO: 1 This gene is expressed primarily in testes tumor and to a lesser extent in fetal brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue{s) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly of the testes, and defects of the central nervous system such as seizure and neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly cancer of the testes and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testes and other reproductive tissue, brain and other tissue of the nervous system, and blood cells, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal S fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of testicular cancer and treatment of central nervous system disorders since this gene is primarily expressed in the testes tumor and developing brain.
FEATURES OF PROTEIN ENCODED BY GENE NO: 2 This gene is expressed primarily in cancer tissues, such as breast cancer and IS Wilm's tumor, and to a lesser extent in fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and/or tumors, particularly, those found in the breast, and developmental abnormalities or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the glandular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary 2S tissue, and fetal tissue and, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 314 as residues: Pro-11 to Thr-18, Leu-43 to Pro-S0, Gly-64 to Leu-72, and Leu-81 to Lys-86.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of cancers and/or tumors, particularly, those found in the breast since expression is mainly in cancer/tumor 3S tissues. May serve as therapeutic proteins for proliferation/differentiation of fetal tissues.
r ~

WO 98!39448 PCT/US98/04493 FEATURES OF PROTEIN ENCODED BY GENE NO: 3 This gene is expressed primarily in CD34 depleted huffy coat and to a lesser extent in spleen, chronic lymphocytic leukemia.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: blood disorders or leukemias, diseases of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders or leukemias, diseases of the immune system since expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 4 This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: blood disorders or lymphocytic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid] or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

H
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders since expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 5 This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: blood or immune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 317 as residues:
Pro-13 to Lys-21.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders since expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 6 This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: blood or immune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 31$ as residues:
Lys-31 to Lys-39.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood diseases since it is expressed in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 7 This gene is expressed primarily in CD34 depleted buffy coat and to a lesser extent in pineal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases of the immune system and brain associated diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and pineal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of blood disorders, immune diseases or brain associated diseases (specifically of the pineal gland) since expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 8 The translation product of this gene shares sequence homology with an organic cation transporter which is thought to be important in organic cation uptake in the kidney and liver. (See Accession No. 2343059.) Preferred polypeptide fragments comprise the amino acid sequence ITIAIQMICLVNXELYPT'FVRNXGVMVCSSLCDIGGIITP
FIVFRLREVWQALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENLGRKAKPKENTIYLK
VQTSEPSGT (SEQ ID NO: 615) or TMKDAENLGRKAKPKENT (SEQ ID NO: 616) as well as N-terminal and C-terminal deletions of these fragments. Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in liver.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hepatic and renal 5 diseases where drug elimination/cation exchange (organic cation uptake) in the liver and kidney are problematic. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic or renal system, expression of this gene at significantly higher 10 or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 320 as residues: Asn-64 to Asn-74, and Gln-81 to Gly-87.
The tissue distribution and homology to organic canon transporter indicate that polynucleotides and polypeptides corresponding to this gene are useful as a polyspecific transporter that is important for drug elimination in the liver (and possibly kidney) since expression is found in the liver.
FEATURES OF PROTEIN ENCODED BY GENE NO: 9 This gene is expressed primarily in eosinophil induced with IL-5 and to a lesser extent in fetal liver and spleen. This gene also maps to chromosome 15, and therefore can be used in linkage analysis as a marker for chromosome 15.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases of the immune system, particularly allergies or asthma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating/diagnosis of diseases involving esosinphil reactions since expression seems to be concentrated in eosinophils and other tissues involved in immunity such as the liver and spleen.
FEATURES OF PROTEIN ENCODED BY GENE NO: 10 This gene is expressed primarily in tissues of hematopoietic lineage and to a lesser extent in Hodgkins lymphoma. Any frame shifts in this sequence can easily be clarified using known molecular biology techniques.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and immune deficiency or dysfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, lymphoid and reticuloendothelial tissues, and cancerous tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/ diagnosis for lymphomas or immune dysfuction or as a therapeutic protein useful in immune modulation based on expression in anergic T-cells and lymphomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 11 This gene is expressed primarily in neutrophils and to a lesser extent in activated lymphoid cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the cell type present in a biological sample and for diagnosis of diseases and conditions: inflamation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 323 as residues: Glu-40 to Lys-46.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for modulation of an immune reaction or as a growth factor for the differentiation or proliferation of neutrphils for the treatment of neutropenia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 12 This gene is expressed primarily in brain and to a lesser extent in activated T-cells. It is likely that the open reading frame containing the predicted signal peptide continues in the 5' direction. Preferred polypeptide fragments comprise the amino acid sequence PRVRNSPEDLGLSLTGDSCKL (SEQ ID N0:617).
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions:
neurodegenerative disorders including ischemic shock, alzheimers and cognitive disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and brain, and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 324 as residues: Ser-5 to Glu-14, Ile-21 to Pro-35, Ser-65 to Asp-81, Cys-89 to Val-96, Lys-136 to Ser-145, Ile-152 to Met-169, and Arg-189 to Lys-196.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnostic/treatment for cancers of the given tissue or in the treatment of neurological disorders of the CNS.
~ ...~...

t3 FEATURES OF PROTEIN ENCODED BY GENE NO: 13 This gene was also recently cloned by other groups, naming this calcium-activated potassium channel gene, hKCa4. (See Accession No. AF033021, see also, Accession No. 2584866.) This gene is mapped to human chromosome 19q13.2. A second signal sequence likely exists upstream from the predicted signal sequence as described in Table 1. Preferred polypeptide fragments comprise: QADDLQATVAALCVLRGGGPWAG
SWLSPKTPGAMGGDLVLGLGALRRRKRLL (SEQ NO: 618); or EQEKSLAGWALVLAXXGIGL
MVLHAEMLWFGGCSAVNATGHLSDTLWLIPITFLTIGYGDVVPGTMWGKIVCLCTGVMGVCC
TALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAARVLQEAWMFYKHTRRKESHAAR
XHQRXLLAAINAFRQV RLKHRKLREQVNSM VDIS KMHMILYDLQQNLSSSHRALEKQIDTLAG
KLDALTELLSTALGPRQLPEPSQQSK (SEQ ID NO: 619), as well as N-terminal and C-terminal deletions. Also preferred are polynulcleotide fragments encoding these polypeptide fragments.
I S This gene is expressed primarily in breast lymph node and T-cells, and to a lesser extent in placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hematologic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lymphoid tissue, blood cells and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 325 as residues: Arg-13 to Lys-23.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/diagnosis of hematologic and diseases involving immune modulation based or distribution in the lymph node and T-cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14 This gene was recently cloned by another group, calling it PAPS synethase.
(See Accession No. e1204135.) Preferred polypeptide fragments comprise the amino acid sequence YQAHHVSRNKRGQVVGTRGGFRGCTVWLTGLSGAGK (SEQ ID NO: 620).
Also preferred are the polynucleotide fragments encoding this polypeptide fragment.
It has been discovered that this gene is expressed primarily in benign prostate hyperplasia, Human Umbilical Vein Endothelial Cells and to a lesser extent in smooth muscle and Human endometrial stromal cells-treated with estradiol.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: inflamation, ischemia, and restenosis, based on endothelial cell and smooth muscle cell expression, and prostate diseases such as benign prostate hyperplasia or prostate cancer.
Similarly, polypeptides and antibodies directed to these poiypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate or vessels of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate, endothelial cells, smooth muscle, and endometrium, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 326 as residues: Arg-21 to Asp-26, Lys-35 to Lys-44, Glu-49 to Asn-58.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating/diagnosing diseases or conditions where the endothelial cell lining of the veins and arteries of underlying smooth muscle are involved.
FEATURES OF PROTEIN ENCODED BY GENE NO: 15 This gene is expressed primarily in human 6 week embryo and to a lesser extent in placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: developmental anomalies or fetal deficiencies. Similarly, polypeptides and antibodies directed to these T ,. r polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly developmental in nature, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic 5 tissue, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
10 NO. 327 as residues Lys-50 to Glu-57.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of developmental abnormalities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 16 15 This gene is expressed primarily in kidney and amygdala and to a lesser extent in fetal tissues. This gene is mapped to chromosome 14, and therefore is useful in linkage analysis as a marker for chromosome 14.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) present in a biological sample and for diagnosis of diseases and conditions: kidney diseases, neurological disorders and developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s). For a number of disorders of the above tissues, particularly of the renal system or developing fetal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, amygdala, and fetal tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of conditions affecting the brain, kidneys and fetal development.
FEATURES OF PROTEIN ENCODED BY GENE NO: 17 This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are usefizl as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: solid tumors similar to ovarian cancer Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system. expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovarian and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, IO plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 329 as residues Ser-51 to Val-56.
I S The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of solid tumors of the reproductive system such as ovarian cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 18 This gene is expressed primarily in brain medulloblastoma._ Preferred polypeptide fragments comprise the amino acid sequence: IRHEQHPNFSLEMHSKGSSLLLFLPQL
ILILPVCAHLHEELNC (SEQ ID NO: 643) and SFFISEEKGHLLLQAERHPWVAGALVGVSG
GLTLTTCSGPTEKPATKNYFL,KRLLQEMHIRAN (SEQ ID NO: 644), as well as N-terminal and C-terminal deletions. Also preferred are polynucleotide fragments encoding these polypeptide fragments.
20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors particularly of the CNS or Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) 25 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell 30 sample taken from an individual having such a disorder, relative to the standard gene ~ T

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating medulloblastoma or similar tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 19 This gene is expressed primarily in adipocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: obesity.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adipose tissues expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipocytes and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating obesity by regulating the function and number of adipocytes FEATURES OF PROTEIN ENCODED BY GENE NO: 20 This gene is expressed primarily in B cell lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of the immune system with an emphasis on B cell lymphoma.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumors of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell derived tumors based on its expression in b cell lymphomas FEATURES OF PROTEIN ENCODED BY GENE NO: 21 This gene is expressed primarily in immune cells and to a lesser extent in fetal tissues Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: inflammatory diseases Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cells of the immune system, and fetal tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
N0:333 as residues Asp-10 to Pro-19, Ser-74 to Tyr-79, Glu-95 to Lys-110.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of diseases involving alterations in T
cell activity.
FEATURES OF PROTEIN ENCODED BY GENE NO: 22 It has been discovered that this gene is expressed primarily in ovarian tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors particularly of the ovary. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of tumors of the reproductive organs. expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovarian T ,r and other reproductive tissue and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 334 as residues: Leu-22 to Gln-27.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovarian tumors as it has only been identified in ovarian tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 23 It has been discovered that this gene is expressed primarily in fetal tissues and to a lesser extent in osteoclastoma cell line Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues} or cell types) present in a biological sample and for diagnosis of diseases and conditions: osteoporosis or arthritis Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone cells, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of conditions of abnormal bone remodeling due to enhanced activity of osteoclasts. This may be useful as a specific marker for malignancies derived from osteoclasts or their precursors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 24 The translation product of this gene shares sequence homology with a periplasmic ribonuclease which is thought to be important in degrading extracellular polynucleotides It has been discovered that this gene is expressed primarily in serum treated smooth muscle cells WO 98!39448 PCT/US98/04493 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: vascular disease such as restenosis. Similarly, polypeptides and antibodies directed to these polypeptides are 5 useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vasculature expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g.> smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or 10 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 336 as residues:
Gln-30 to Lys-36, and Pro-41 to Arg-48.
15 The tissue distribution and homology to ribonucleases indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of pathological conditions of smooth muscle associated with bacterial or viral infiltration FEATURES OF PROTEIN ENCODED BY GENE NO: 25 20 This gene is expressed primarily in Early Stage Human Brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: human brain development and related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain development and related diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to this gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases affecting human brain development and related diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26 It has been discovered that this gene is expressed primarily in human brain tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: human brain diseases and other diseases related to brain diseases, which may be caused by brain diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of human brain diseases and other diseases related.
FEATURES OF PROTEIN ENCODED BY GENE NO: 27 It has been discovered that this gene is expressed primarily in Anergic T-cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune diseases, inflammatory diseases and diseases related to T lymph cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune diseases, inflammatory diseases and diseases related to T lymph cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types {e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for immune diseases, inflammatory diseases and diseases related to T lymph cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 28 The translation product of this gene shares sequence homology with Shigella flexneri positive transcriptional regulator CriR (criR) gene which is thought to be important in regulation of gene expression.
This gene is expressed primarily in human synovial sarcoma and normal human brawn tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: human brain diseases particularly sarcomas of the synovium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human brain and synovium and other related human brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., synovial tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of human synovial sarcoma and other related human brain diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 29 This gene is expressed in bone marrow, infant brain, fetal liver and spleen, prostate and to a lesser extent in pineal gland, adipose tissue, kidney, adrenal gland, umbilical vein endothelial cells, and T cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases related to bone marrow or r hematoplastic tissues, prostate, kidney, adrenal gland, and cardiovascular tissue or organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases related to hematoplastic tissues, immune system, prostate, kidney, adrenal gland, and cardiovascular tissue or organs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, hematopoietic cells, pineal gland, adipose tissue, kidney, adrenal gland, endothelial cells, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases related to hematoplastic tissues, immune system, prostate, kidney, adrenal gland, and cardiovascular tissue or organs.
FEATURES OF PROTEIN ENCODED BY GENE NO: 30 This gene is expressed primarily in meningea and to a lesser extent in breast and adult brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Diseases of the meningea and related brain diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the meningea and related brain diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., miningea, mammary tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the meningea and related brain diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 31 This gene is expressed in meningea, fetal spleen, osteoblast and to a lesser extent in activated T-cells, endometrial stromal cells, fetal lung, HL-60, thymus, testis and endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: meningeal disease, osteoporosis, immune diseases, and hematoplastic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the meningeal diseases, osteoporosis, immune diseases, and hematoplastic diseases, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, endometrium, lung, thymus, testis, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of meningeal, osteoporosis, immune diseases, hematoplastic diseases, testis diseases and lung diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 32 This gene is expressed primarily in human thymus and to a much lesser extent in infant brain, T-cells, smooth muscle, endothelial cells, bone marrow, human ovarian tumor and keratinocytes testes, osteoclastoma, breast, and tonsils.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Diseases involving the thymus, particularly thymic cancer and diseases involving T-cell maturation.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). Far a r. fi number of disorders of the above tissues or cells, particularly of the thymus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., thymus, brain, and other tissue of the nervous system, blood cells, bone marrow, ovaries, and testes, and other reproductive tissue, mammary 5 tissue, tonsils, melanocytes and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
10 The tissue distribution and homology to gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the thymus particularly thymic cancer and diseases involving T-cell maturation.
15 FEATURES OF PROTEIN ENCODED BY GENE NO: 33 This gene is expressed primarily in human tonsils, and placenta, and to a lesser extent in adipocytes, melanocyte, and infant brain.
Therefore, poiynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a 20 biological sample and for diagnosis of diseases and conditions:
inflammatory diseases, immune diseases, and obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory diseases, immune diseases, and obesity, expression of 25 this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., tonsils, placenta, adipocytes, melanocytes, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to this gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases such as inflammation, immune diseases, and obesity.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34 This gene is expressed in activated T cells, and to a lesser extent in pituitary, testis, and breast lymph node.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases relating to T
cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the disorders of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pituitary, testes and other reproductive tissue, mammary tissue, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 35 This gene is expressed primarily in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases relating to neurological disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain, and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological disorders.
~. r FEATURES OF PROTEIN ENCODED BY GENE NO: 36 This gene is expressed primarily in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the diseases relating to neurological disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 37 This gene is expressed primarily in human ovary.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: ovarian cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ovarian disorders such as those involving germ cells, ovarian follicles, stromal cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovary and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovariopathy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38 This gene is expressed primarily in lymph node breast cancer.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: breast cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast cancer, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for used as a diagnostic marker for breast cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 39 This gene is expressed primarily in brain and to a lesser extent in other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neuronal disorders such as trauma, brain degeneration, and brain tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and therapeutic treatment of neuronal disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40 This gene is expressed in early stage human embryo, adrenal gland tumor, and immune tissues such as fetal liver, fetal spleen, T-cell, and myoloid progenitor cell line and to a lesser extent in ovary, colon cancer, and a few orther tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumorigenesis including adrenal gland tumor, colon cancer and various other tumors, developmental and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancer tissues, early stage human tissues, and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, blood cells, bone marrow, ovary and other reproductive tissue, and colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and therapeutic treatment of immune and developmental disorders, and tumorigenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 41 This gene is expressed primarily in fetal lung, endothelial cells, liver, thymus and a few other immune tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune disorders such as immune deficiency and autoimmune diseases, pulmonary diseases, liver diseases, and tumor matasis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal lung, liver, endothelial cells, and immune tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lung, endothelial cells, liver, thymus, and other tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., 5 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of immune disorders and pulmonary and hepatic diseases. Its promoter may also be used for immune system and lung-10 specific gene therapies. The expression of this gene in endothelial cells indicates that it may also involve in angiogenesis which therefore may play role in tumor matasis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 42 This gene is expressed primarily in liver, thyroid, parathyroid and to a lesser I S extent in fetal lung, stomach and early embryos.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: metabolic regulation, obesity, heptic failure, heptacellular tumors or thyroiditis and thyroid tumors. Similarly, 20 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive/endocrine system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, thyroid, parathyroid, lung, 25 stomach, and embryonic tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
30 The tissue distribution and the extracellular locations indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of digestivelendocrine disorders, including metabolic regulation, heptic failure, malabsortion, gastritis and neoplasrns.
r FEATURES OF PROTEIN ENCODED BY GENE NO: 43 This gene is expressed primarily in Schizophrenic adult brain, pituitary, front cortex, hypothalmus and to a lesser extent in retina, adipose and stomach cancer and placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: schizophrenia and other neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nerve system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., retinal tissue, adipose, stomach, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in treatmentldetection of disorders in the nerve system, including schizophrenia, neurodegeneration, and neoplasia.
Additionally, a secreted protein in brain may serve as an endocrine.
FEATURES OF PROTEIN ENCODED BY GENE NO: 44 The translation product of this gene shares sequence homology with GTP
binding proteins which are thought to be important in signal transduction and protein transport.
This gene is expressed primarily in umbilical vein and microvascular endothelial cells, GM-CSF treated macrophage, anergic T cells, osteoblast, osteoclast, CD34+ cells and to a lesser extent in gall bladder.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: bone formation and growth, osteonecrosis, osteoporosis, angiogenesis and/or hematopoeisis.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and hematopoeisis systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endothelial cells, blood cells, bone, and gall bladder, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to GTP binding proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment/detection of bone formation and growth, osteonecrosis, osteoporosis, and/or hematopoeisis because its involvement in the growth signaling or angiogenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 45 The translation product of this gene shares sequence homology with signal sequence receptor gamma subunit which is thought to be important in protein translocation on endoplasmic reticulum.
This gene is expressed primarily in adrenal gland, salivary gland, prostate, and to a lesser extent in endothelial cells and smooth muscle.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: protein secretion.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the secretory organs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adrenal gland, salivary gland, prostate, endothelial cells, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to SSR gamma subunit indicate that polynucleotides and polypeptides corresponding to this gene are useful for endocrine disorders, prostate cancer, xerostomia or sialorrhea.
FEATURES OF PROTEIN ENCODED BY GENE NO: 46 This gene is expressed primarily in osteoclastoma cells and to a lesser extent in melanocyte, amygdala, brain, and stomach.
r i Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: ossification, - osteoporosis, fracture, osteonecrosis, osteosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., melanocytes, amygdala, brain and other tissue of the nervous system, and stomach, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in intervention of ossification, osteoporosis, fracture, osteonecrosis and osteosarcoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 48 The translation product of this gene shares sequence homology with proline rich proteins which is thought to be important in protein-protein interaction.
This gene is expressed primarily in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological and psychological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nerve system and endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to proline-rich proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful in intervention and detection of neurological diseases, including trauma, neoplasia, degenerative or metabolic conditions in the central nerve system. Additionally, the gene product may be a secreted by the brain as an endocrine.
FEATURES OF PROTEIN ENCODED BY GENE NO: 49 The translation product of this gene shares sequence homology with the AOCB
gene from Aspergillus nidulans which is important in asexual development.
This gene is expressed primarily in infant brain and to a lesser extent in the developing embryo, trachea tumors, B-cell lymphoma and synovial sarcoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions:
neurodegenerative diseases, leukemia and sarcoma's. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential 1 S identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, blood cells, trachea, and synovial tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution in infant brain and sarcoma's and homology to a gene involved in a key step of eukaryotivc development (fungal spore formation) indicates that the protein product of this clone could play a role in neurological diseases such as schizophrenia, particularly in infants. The existence of the gene in a B-cell lymphoma indicates the gene may be used in the treatment and detection of leukemia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 50 This gene is expressed primarily in fetal lung.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: pulmonary disorders including lung cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or r r lower levels may be routinely detected in certain tissues and cell types (e.g., lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level 5 in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution of this gene only in fetal lung indicates that it plays a key role in development of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung. It may also be involved in predisposition to certain 10 pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 51 This gene is expressed primarily in hernatopoietic cell types and fetal cells and to 15 a lesser extent in all tissue types.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects in the immune system and hematopoeisis. Similarly, polypeptides and antibodies directed to these 20 polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and fetal tissue, and cancerous and wounded tissues) 25 or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution of this gene predominantly in hematopoeitic cells and in 30 the developing embryo indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of lymphomas and disease states affecting the immune system or hematopoeisis disorders such as leukemia, AIDS, arthritis and asthma..
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 52 This gene is expressed primarily in prostate and to a lesser extent in fetal spleen, fetal liver, infant brain and T cell leukemias.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: prostate disorders, prostate cancer, leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, and/or prostate gland expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., thymus, spleen, liver, brain and other tissue of the nervous system, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution of this gene in prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection or treatment of prostate disorders or prostate cancer. Its distribution in fetal liver and fetal spleen indicates it may play a role in the immune system and its misregulation could lead to immune disorders such as leukemia, arthritis and asthma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 53 The translation product of this gene shares sequence homology with dynein.
This gene is expressed primarily in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neuro-degenerative diseases of the brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly neuro-degenerative diseases expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
r r The predominant tissue distribution in the brain and homology to dynein, a microtubule motor protein involved in the positioning of cellular organelles and molecules indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection/treatment of neurodegenerative diseases, such as Alzheimers, Huntigtons, Parkinsons diseases and shizophrenia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 54 The translation product of this gene shares sequence homology with ubiquitin-conjugation protein, an enzyme which is thought to be important in the processing of the Huntingtons Disease causing gene.
This gene is expressed primarily in brain and to a lesser extent in activated macrophages.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a I S biological sample and for diagnosis of diseases and conditions:
neurodegenerative disease states including Huntington's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of brain tissues. For a number of disorders of the above tissues or cells, particularly of the neurological systems expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types {e.g., brain and other tissue of the nervous system, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The predominant tissue distribution of this gene in the brain and its homology to a Huntington interacting protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the regulation of the expression of the Huntington disease gene and other neurodegenerative diseases including spinocerebullar ataxia types I and III, dentatorubropallidoluysian and spinal bulbar muscular atrophy. In addition, the existence of elevated levels of free ubiquitin pools in Alzheimer's disease, Parkinson's disease and amylotrophic lateral sclerosis indicates that the ubiquitin pathway of protein degradation plays a role in these disease states.
Thus, considering the gene described here is homologous to a ubiquitin-conjugation protein it may play a general role in neurodegenarative conditions.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56 This gene is expressed primarily in T-cells (anergic T-cells, resting T-Cells, apoptotic T-cells) and lymph node (breast), as well as brain (hypothalamus, hippocampus, pituitary, infant brain, early-stage brain).
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune (e.g.
immunodeficiencies, autoimmunities, inflammation, leukemias & lymphomas) and neurological (e.g. Alzheimer's disease, dementia, schizophrenia) disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous, hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, lymphoid tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in the intervention or detection of pathologies associated with the hematopoietic and immune systems, such as anemias (leukemias).
In addition, the expression in brain (including fetal) might suggest a role in developmental brain defects, neuro-degenerative diseases or behavioral abnomalities (e.g. schizophrenia, Alzheimer's, dementia, depression, etc.).
FEATURES OF PROTEIN ENCODED BY GENE NO: 57 This gene is expressed primarily in lung, and to a lesser extent in a variety of other hematological cell types (e.g. Raji cells, bone marrow cell line, activated monocytes).
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: pulmonary and/or hematological disfunction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vasculo-pulmonary and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lung and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in the intervention and detection of pathologies associated with the vasculo-pulmonary system. In addition the expression of this gene in a variety of leukocytic cell types and a bone marrow cell line might suggest a role in hematopoietic and immune system disorders, such as leukemias & lymphomas, inflammation, immunodeficiencies and autoimmunities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 58 The translation product of this gene shares sequence homology with adenylate kinase isozyme 3 (gi1163528 GTP:AMP phosphotransferase {EC 2.7.4.10) [Bos taurus]), which is thought to be important in catalyzing the phosphorylation of AMP to ADP in the presence of ATP or inorganic triphosphate.
This gene is expressed primarily in fetal liver, heart and placenta, and to a lesser extent in many other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hepatic, cardiovascular or reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic, cardiovascular and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, heart, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions related to hepatic function and pathogenesis, in particular, those dealing with liver development and the differentiation of hepatocyte progenitor cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59 This gene is expressed primarily in CD34 positive cells (Cord Blood).
Therefore, polynucleotides and polypeptides of the invention are useful as 5 reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hematopoietic differentiation and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above 10 tissues or cells, particularly of hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to 15 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in the detection and treatment of conditions associated with CD34-positive cells, and therefore as a marker for cell differentiation in 20 hematapoiesis, as well as immunological disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 60 The translation product of the predicted open reading frame of this contig has sequence identity to the murine gene designated Insulin-Like Growth Factor-Binding 25 Protein (IGFBP)-1 as described by Lee and colleagues (Hepatology 19 (3), ( 1994)).
This gene is expressed exclusively in hemangiopericytoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a 30 biological sample and for diagnosis of hemangiopericytoma and other pericyte or endothelial cell proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and immune systems, expression of this 35 gene at significantly higher or lower levels may routinely be detected in certain tissues and cell types (e.g., pericyte or endothelial cells, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or t 4t another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
Polynucleotides and polypeptides corresponding to this gene are useful as cell growth regulators since IGFBP-1-like molecules function as modulators of insulin-like growth factor activity. In addition, since IGFBP-1 is expressed at high levels following hepatectomy and during fetal liver development, polynucleotides of the present invention may also be used for the diagnosis of developmental disorders.
Further, polypeptides of the present invention may be used therapeutically to treat developmental liver disorders as well as to regulate hepatocyte and supporting cell growth following hepatectomy or to treat liver disorders.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hemangiopericytoma and liver disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: bl This gene is expressed primarily in schizophrenic frontal cortex.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: nervous system and cognitive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the frontal cortex and CNS expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of frontal cortex, neuro-degenerative and CNS disorders FEATURES OF PROTEIN ENCODED BY GENE NO: 62 This gene is expressed primarily in human adrenal gland tumor, and to a lesser extent in human kidney, medulla and adult pulmonary tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: metabolic, endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and nervous system disorders and neoplasia, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adrenal gland, kidney, brain and other tissue of the nervous system, pulmonary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of neurological and endocrine disorders including neoplasia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 63 This gene is expressed primarily in human adipocytes, and to a lesser extent in spleen, 12-week old human, and testes.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune, metabolic and growth disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipocytes, spleen, and testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of immune, developmental and metabolic disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64 One translated product of this clone is homologous to the mouse zinc finger protein PZF. (See Accession No. 453376; see also Gene 152 (2), 233-238 ( 1995).) Preferred polypeptide fragments correspond to the highly conserved domains shared between mouse and man. For example, preferred polypeptide fragments comprise the amino acid sequence: LQCEICGFTCRQKASLNWHMKKHDADSFYQFSCNICGKKFEKKDSVVAHKAKSH
PEV (SEQ ID NO: 621 ); ITSTDILGTNPESLTQPSD (SEQ ID NO: 622); NSTSGECLLLEAEGM
SKSY (SEQ ID NO: 623); CSGTERVSLMADGKIFVGSGSSGGTEGLVMNSDILGATTEVLIEDSD
SAGP (SEQ ID NO: 624); IQYVRCEMEGCGTVLAHPRYLQHHIKYQHLLKKKYVCPHPSCGRLF
RLQKQLLRHAKHHT (SEQ ID NO: 625); DQRDYICEYCARAFKSSHNLAVHRMIHTGEK (SEQ
ID NO: 626); RSSRTSVSRHRDTENTRSSRSKTGSLQLICKSEPNTDQLDY (SEQ ID NO: 627);
PFKDDPRDETYKPHLERETPKPRRKSG (SEQ ID NO: 630); QYVRCEMEGCGTVLAHPRYLQ
HHIKYQHLLKKKYVCPHPSCGRLFRLQKQLLRHAKHHTD (SEQ ID NO: 629); or residues 151-182 of QRDYICEYCARAFKSSHNLAVHRMIHTGEKHY (SEQ ID NO: b28). Also preferred are polynucleotide fragments encoding these polypeptide fragments.
This gene is expressed primarily in Rhabdomyosarcoma, melanocyte and colon cancer tissue and to a lesser extent in smooth muscle, pancreatic tumor, and apoptotic T-cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hemopoetic, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., striated muscle, melanocytes, colon, smooth muscle, pancreas, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis and treatment of cancer and hemopoetic disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65 This gene is expressed primarily in human adipose and salivary gland tissue and to a lesser extent in human bone marrow and fetal kidney.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: metabolic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and hemopoetic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipose, salivary gland, bone marrow, and kidney, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis of metabolic and immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 66 This translated product of this gene was recently identified as oxytocinase splice variant 1. (See Accession Nos. 2209276 and d1010078.) Preferred polypeptide fragments comprise the amino acid sequence: EMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHN
HSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMK
PEIQPSDTRYM (SEQ ID NO: 631 ). Also preferred are polynucleotide fragments encoding this polypeptide fragment.
FEATURES OF PROTEIN ENCODED BY GENE NO: 67 This gene is expressed primarily in hemopoetic cells, particularly apoptotic T-cells, and to lesser extent in primary dendritic cells and adipose tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of apoptotic T-cells, primary denritic cells, and adipose tissue present in a biological sample and for diagnosis of diseases and conditions: hemopoetic diseases including cancer and general immune disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell r ?

type(s). For a number of disorders of the above tissues or cells, particularly of the oral and intestinal mucosa as well as hemopoetic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and cancerous and wounded tissues) or bodily 5 fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides 10 corresponding to this gene are useful for treatment of diseases of the immune system, including cancer, hemopoetic and infectious diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 68 This gene is expressed primarily in kidney cortex and to a lesser extent in infant 15 brain, heart, uterus, and blood.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of kidney tissue present in a biological sample and for diagnosis of diseases and conditions: soft tissue cancer, inflammation, kidney fibrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful 20 in providing immunological probes for differential identification of the tissues) or cell type{s). For a number of disorders of the above tissues or cells, particularly of the nervous and endocrines systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, brain, and other nervous tissue, heart, uterus, and blood cells, and cancerous and 25 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides 30 corresponding to this gene are useful for study and treatment of cancer and fibroses.
FEATURES OF PROTEIN ENCODED BY GENE NO: 69 The translation product of this gene shares strong sequence homology with vertebrate and invertebrate protein tyrosine phosphatases.
35 This gene is expressed primarily in endometrial tumors, melanocytes, myeloid progenitors and to a lesser extent in infant brain, adipocytes, and several hematopoietic stem cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of transformed hematopoietic and epithelial cells present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of skin and endometrium, leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and hemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, melanocytes, bone marrow, adipocytes, hematopoietic cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and sequence similarity with tyrosine phosphatases indicate that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of cancer and hematopoietic disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 70 This gene is expressed primarily in osteoclastoma, breast, and infant brain and to a lesser extent in various fetal and transformed bone, ovarian, and neuronal cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: degenerative conditions of the brain and skeleton. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, mammary tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
1.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of degenerative, neurological and skeletal disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 71 This gene was originally cloned from tumor cell lines. Recently another group has also cloned this gene, calling it the human malignant melanoma metastasis-suppressor (KISS-1) gene. (See Accession No. U43527.) Preferred polypeptide fragments comprise the amino acid sequence: LEKVASVGNSRPTGQQLESLGLLA (SEQ ID
NO: 632); VHREEASCYCQAEPSGDL {SEQ ID NO: 633); RPALRQAGGGTREPRQKRWAGL
(SEQ ID NO: 634); and AVNFRPQRSQSM (SEQ ID NO: 635). Any frame shifts can easily be resolved using known molecular biology techniques.
This gene is expressed primarily in many types of carcinomas and to a lesser extent in many normal organs.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues(s) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly melanomas, and other hypeiproliferative disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of transformed organ tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. As a tumor suppressor gene, increase amounts of the polypeptide can be used to treat patients having a particular cancer.
The tissue distribution indicates that this gene and the translated product is useful for diagnosing and study of cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 72 This gene is expressed primarily in striatum and to a lesser extent in adipocytes and hemangioperiocytoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of striatal cells present in a biological sample and for diagnosis of diseases and conditions: neurological, fat and lysosomal storage diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., striatal tissue, adipocytes, and vascular tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, study and treatment of neurodegenerative and growth disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 73 This gene is expressed primarily in bone marrow stromal cells and to a lesser extent in smooth muscle, testes, endothelium, and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of bone marrow present in a biological sample and for diagnosis of diseases and conditions: connective tissue and hematopoietic diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, stromal cells, smooth muscle, testes and other reproductive tissue, endothelium, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids {e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynueleotides and polypeptides corresponding to this gene are useful for study, diagnosis, and treatment of connective tissue and blood diseases.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74 This gene is expressed primarily in brain, fetal liver and lung and to a lesser extent in retina, spinal chord, activated T-cells and endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of brain and regenerating liver present in a biological sample and for diagnosis of diseases and conditions: CNS and spinal chord injuries, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, pulmonary tissue, blood cells, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of hematopoietic and neurological conditions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 75 The translation product of this gene shares sequence homology with GTP
binding proteins (intracellular).
This gene is expressed primarily in bone marrow, brain, and melanocytes and to a lesser extent in various endocrine and hematopoietic tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hematopietic and nervous system conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, melanocytes, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to nucleotide binding factors indicate that polynucleotides and polypeptides corresponding to this gene are useful for study, 5 diagnosis, and treatment of brain degenerative, skin and blood diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 76 This gene is expressed primarily in activated T-cells and to a lesser extent in retina, brain, and fetal bone.
10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of activated T-cells and developing brain present in a biological sample and for diagnosis of diseases and conditions: immune deficiencies and skeletal and neuronal growth disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes 15 for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, immune, and skeletomuscular sustems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, brain and other tissue of the nervous system, retinal tissue, and bone, and cancerous and wounded tissues) or 20 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid}
or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides 25 corresponding to this gene are useful for diagnosis, study and treatment of cancer, urogenital, and brain degenerative diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 77 This gene is expressed primarily in fetal liver, activated monocytes, osteoblasts 30 and to a lesser extent in synovial, brain, and lymphoid tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of myeloid and lymphoid present in a biological sample and for diagnosis of diseases and conditions: inflammation, immune deficiencies, cancer. Similarly, polypeptides and antibodies directed to these 35 polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and skeleton, expression of this gene at significantly t r higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, blood cells, bone, synovial tissue, brain and other tissue of the nervous system, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, diagnosis, and treatment of lymphoid and mesenchymal cancers and nervous system diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 78 The translation product of this gene shares sequence homology with polymerase polyprotein precursor which is thought to be important in DNA repair and replication This gene is expressed primarily in infant brain and to a lesser extent in tumors and tumor cell lines Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, especially of the neural system and developing organs.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to polymerase polyprotein precursor indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers especially of the neural system and developing organs FEATURES OF PROTEIN ENCODED BY GENE NO: 79 This gene is expressed primarily in muscle and endothelial cells and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: vascular diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues}
or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., muscle, endothelial cells, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the vascular and neural system including cardiovascular and endothelial.
FEATURES OF PROTEIN ENCODED BY GENE NO: 80 This gene is expressed primarily in placenta and to a lesser extent in fetal liver Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: developmental disorders and disorder of the haemopoietic system, fetal liver and placenta. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue{s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developmental disorders and disorder of the haemopoietic system, fetal liver and placenta, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid} or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders and disorders of the haemopoietic system, fetal liver and placenta.
r ~

FEATURES OF PROTEIN ENCODED BY GENE NO: 81 This gene is expressed primarily in bone marrow, placenta and tissues and organs of the hematopoietic system.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: disorders of the bone and haemopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification IO of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, bone and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone marrow, placenta, and hematopoietic cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal i 5 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the 20 immune, bone and hematopoietic system FEATURES OF PROTEIN ENCODED BY GENE NO: 82 The translation product of this gene shares sequence homology with secretory carrier membrane protein which is thought to be important in protein transport and 25 export. Any frame shifts in coding sequence can be easily resolved using standard molecular biology techniques. Another group recently cloned this gene, calling it SCAMP. (See Accession No. 2232243.) This gene is expressed primarily in prostate, breast and spleen, and to a lesser extent in several other tissues and organs.
30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: disorders of the breast prostate and spleen. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification 35 of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly disorders of the breast prostate and spleen, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate, mammary tissue, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synoviai fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to secretory carrier membrane protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the breast, prostate and spleen.
FEATURES OF PROTEIN ENCODED BY GENE NO: 83 This gene is expressed primarily in developing organs and tissue like placenta and infant brain and to a lesser extent in developed organs and tissue like cerebellum and heart.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, heart, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the neural system including neurological disorders and cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 84 The translation product of this gene shares sequence homology with ATPase 6 in Trypanosoma brucei which is thought to be important in metabolism.
This gene is expressed primarily in tumor and fetal tissues and to a lesser extent in melanocytes, kidney cortex, monocytes and ovary.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: metabolism disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal 5 systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissues, melanocytes, kidney, blood cells, ovary and other tissue of the reproductive system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to 10 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ATPase indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of metabolism disorders, especially in fetal and tumor tissue growth.
FEATURES OF PROTEIN ENCODED BY GENE NO: 85 The translation product of this gene shares sequence homology with the immunoglobulin superfamily of proteins which are known to be important in immune response and immunity.
This gene is expressed primarily in stromal cells, colon cancer, lung, amygdala, melanocyte and to a lesser extent in a variety of other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of stromal cell development and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the stromal cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., stromal cells, colon, lung, amygdala, and melanocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to immunoglobulin indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of immune system disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86 The translation product of this gene shares sequence homology with transcription iniation factor eIF-4 gamma which is thought to be important in gene transcription.
This gene is expressed primarily in tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumorigenesis.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly in tumor tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to transcription iniation factor eIF-4 gamma indicate that polynucleotides and polypeptides corresponding to this gene are useful for gene regulation in tumorigenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 87 The translation product of this gene shares sequence homology at low level in prolines with secreted basic proline-rich peptide II-2 which is thought to be important in protein structure or inhibiting hydroxyapatite formation in vitro.
This gene is expressed primarily in endometrial tumor and fetal lung.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: endometrial tumors.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell .
type(s). For a number of disorders of the above tissues or cells, particularly of the muscular/skeletal and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample r r taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- The tissue distribution and homology to secreted basic proline-rich peptide indicate that polynucleotides and polypeptides corresponding to this gene are useful for inhibiting hydroxyapatite formation or establishing celUtissue structure.
FEATURES OF PROTEIN ENCODED BY GENE NO: 88 This gene is expressed primarily in: amniotic cells inducted with TNF in culture;
and to a lesser extent in colon tissue from a patient with Crohn's Disease;
parathyroid tumor; activated T-cells; cells of the human Caco-2 cell line; adenocarcinoma;
colon;
corpus colosum; fetal kidney; pancreas tumor; fetal brain; early stage brain, and anergic T-cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system;
e.g., tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain (e.g., amniotic cells, colon, kidney, pancreas, parathyroid, brain and other tissue of the nervous system, blood cells, hematopoietic cells, liver, spleen, bone, testes and other reproductive tissue, brain and other tissue of the nervous system, and epithelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for modulating tumorigenesis and other immune system conditions such as disorders in immune response.
FEATURES OF PROTEIN ENCODED BY GENE NO: 89 This gene is expressed primarily in fetal liver/spleen and hematopoietic cells and to a lesser extent in brain, osteosarcoma, and testis tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a WO 98/39448 PCT/iTS98/04493 biological sample and for diagnosis of diseases and conditions: leukemia and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, liver, spleen, bone, testes, and other reproductive tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopoietic and 1 S immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 90 The translation product of this gene shares weak sequence homology with mouse Gcap 1 protein which is developmentally regulated in brain.
This gene is expressed primarily in infant and adult brain and fetal liver/spleen and to a lesser extent in smooth muscle, T cells, and a variety of other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, hematopoietic, immune, and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, blood cells, liver, spleen ,and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
T

The tissue distribution and its homology to Gcap 1 protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatubg and diagnosis of disorders in neuronal, hematopoietic, immune, and endocrine systems.
S FEATURES OF PROTEIN ENCODED BY GENE NO: 91 This gene is expressed primarily in brain and hematopoietic cells and to a lesser extent in tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: disorder in nervous, hematopoietic, immune systems and tumorigenesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the in nervous, hematopoietic, immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids {e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of disorders in the nervous, hematopoietic, and immune systems.
FEATURES OF PROTEIN ENCODED BY GENE NO: 92 The translation product of this gene shares sequence homology with neuroendocrine-specific protein A which is thought to be important in neurologic systems.
This gene is expressed primarily in brain tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell typejs) present in a biological sample and for diagnosis of diseases and conditions: neural disorders and degeneration disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central or peripheral nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., hematopoietic cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having 5 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to neuroendocrine-specific protein A
indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of neural disorders and degeneration disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: 93 The translation product of this gene shares sequence homology with collagen-like protein and prolin-rich protein which are thought to be important in connective tissue function and tissue structure.
This gene is expressed primarily in fetal liver/spleen and brain tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neuronal or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to collagen-like protein and proline-rich proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for supporting brain and hematopoietic tissue function and diagnosis and treatment of disorders in these functions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 94 This gene is expressed primarily in embryonic tissues and tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a r i biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system (e.g., tumors), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 95 This gene is expressed primarily in brain tumor, placenta, and melanoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: brain tumor or melanoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain or melanocytes, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, placenta, and melanocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the translation product of this gene is useful in the diagnosis and treatment of brain tumors and melanoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 96 The translation product of this gene shares sequence homology with a yeast membrane protein, SUR4, which encodes for APA 1 that acts on a glucose-signaling pathway that controls the expression of several genes that are transcriptionally regulated by glucose.

This gene is expressed primarily in fetal liver, and to a lesser extent in placenta and breast tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of fetal liver or defects of glucose-regulated ATPase activities in tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal immune/hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, placenta, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to yeast SUR4 membrane protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of defects of fetal liver or defects of glucose-regulated ATPase activities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 97 This gene is expressed primarily in fetal liver, brain, and amniotic fluid.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of the fetal immune system and adult brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal immune system and adult brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and brain and other tissue of the nervous system> and cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for detecting defects of the fetal immune and hematopoietic systems since fetal liver is r the predominant organ responsible for hematopoiesis in the fetus. In addition, the gene product of this gene is thought to be useful for detecting certain neurological defects of the brain.
S FEATURES OF PROTEIN ENCODED BY GENE NO: 98 The translation product of this gene shares sequence homology with an yolk protein precursor, Vitellogenin which is thought to be important in binding lipids such as phosvitin.
This gene is expressed primarily in amniotic cells and fetal liver.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects in amniotic cells, fetal liver development and the fetal immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the [insert system where a related disease state is likely, e.g., immune), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., amniotic cells, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to vitellogenin indicate that the protein product of this clone is useful for treatment and diagnosis of defects in amniotic cells, fetal liver development and the fetal immune system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 99 This gene is expressed primarily in placenta, endometrial tumor, osteosarcoma and stromal cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumor of the endometrium or bone, and osteosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the obstetric system (e.g.
placenta, endometrium) and the bones, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endometrium, bone, and stromal cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumors and abnormalities of the endometrium, and the bones because of its abundance in the aforementioned tissues..
FEATURES OF PROTEIN ENCODED BY GENE NO: 100 This gene is expressed primarily in hepatocellular tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hepatocellular tumor.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of hepatocellular cancer because of its abundant expression in this tissue.
FEATURES OF PROTEIN ENCODED BY GENE NO: 101 This gene is expressed primarily in Corpus Colosum, fetal lung and infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of the Corpus Colosum or defects of the fetal lung. Similarly, polypeptides and antibodies directed to r r these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Corpus Colosum and brain in general, and fetal lung, expression of this gene at significantly higher or lower levels may be routinely detected 5 in certain tissues and cell types (e.g., lung, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the 10 disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of defects of the Corpus Colosum and brain in general, and defects of fetal lung.
15 FEATURES OF PROTEIN ENCODED BY GENE NO: 102 This gene is expressed primarily in T cells and stromal cells, and to a lesser extent in adrenal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a 20 biological sample and for diagnosis of diseases and conditions: defects of T cell immunity and stromal cell development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at 25 significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, stromal cells, and adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily 30 fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of defects of T cell immunity and stromal cell development because of its abundant expression in these tissues.
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 103 This gene is expressed primarily in infant brain and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of the brain and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, especially brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and placenta, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for detecting defects of the brain, especially in young children.
FEATURES OF PROTEIN ENCODED BY GENE NO: 105 This gene is expressed primarily in human osteoclastoma and to a lesser extent in human pancreas tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly osteoclastoma and pancreatic tumor.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly in transformed tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone and pancreas, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of some types of tumors, particularly pancreatic cancer and osteoclastoma.
r FEATURES OF PROTEIN ENCODED BY GENE NO: 106 This gene is expressed primarily in fetal liver/spleen, and to a lesser extent in activated T-Cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 107 This gene is expressed primarily in human embryo and to a lesser extent in spleen and chronic lymphocytic leukemia.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: leukemia.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or hemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, spleen, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for the diagnosis and treatment of leukemia.

WO 98!39448 PCT/US98/04493 FEATURES OF PROTEIN ENCODED BY GENE NO: 108 This gene is expressed primarily in placenta, and to a lesser extent in early stage human brain and in lung.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: fetal developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly in fetal and amniotic tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, brain and other tissue of the nervous system, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this is useful for production of growth factors) associated with fetal development. Preferred polypeptides comprise the full-length polypeptide shown in the sequence listing, truncated however, at the amino terminus and beginning with QTIE.
FEATURES OF PROTEIN ENCODED BY GENE NO: 109 This gene is expressed primarily in fetal spleen, and to a lesser extent in B-Cell lymphoma and T-Cell lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: lymphoma.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue{s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., spleen and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
r The tissue distribution indicates that the protein product of this clone is useful for the treatment and diagnosis of human lymphomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 110 The translation product of this gene shares sequence homology with sarcoma amplified sequence (SAS), a tetraspan receptor which is thought to be important in malignant fibrous histiocytoma and liposarcoma.
This gene is expressed primarily in human osteoclastoma, and to a lesser extent in pineal gland and infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: malignant fibrous histiocytoma and liposarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, pineal gland, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to sarcoma amplified sequence (SAS) indicate that the protein product of this clone is useful for treatment of, osteosarcoma, malignant fibrous histiocytoma and liposarcoma and related cancers, particularly sarcomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 111 The translation product of this gene shares sequence homology with 6.8K
proteolipid protein, mitochondria) - bovine.
This gene is expressed primarily in Wilm's tumor and to a lesser extent in cerebellum and placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Wilm's tumor.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and placenta, and cancerous and wounded tissues) or bodily fluids 5 (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to 6.8K proteolipid protein indicate that 10 the protein product of this clone is useful for diagnostic and therapeutics associated with tumors, particularly Wilm's tumor disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: lI2 This gene is expressed primarily in embryonic tissue and to a lesser extent in 15 osteoblasts, endothelial cells, macrophages (GM-CSF treated), and bone marrow.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in 20 providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g.> embryonic tissue, bone, endothelial cells, blood cells and bone marrow, and cancerous and wounded tissues) or 25 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily t7uid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides 30 corresponding to this gene are useful for treatment or diagnosis of immune disorders.
Preferred polypeptides encoded by this gene comprise the following amino acid sequence: MITDVQLAIFANMLGVSLFLLVVLYHYVAVNNPKKQE (SEQ ID NO: 636).
FEATURES OF PROTEIN ENCODED BY GENE NO: li3 35 This gene is expressed primarily in hepatocellular tumor, and to a lesser extent in fetal liver/spleen.
? ~

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors, particularly hepatocellular tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of tumors, particularly hepatocellular tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 114 The translation product of this gene exhibits a very high degree of sequence identity with the human Pig8 gene which is thought to be important in p53 mediated apoptosis. The sequence of this gene has since been published by Polyak and colleagues (Nature 389, 300-306 ( 1997)). In addition, the predicted translation product of this contig exhibits very high sequence homology with a murine gene denoted as EI24 which is also thought to be important in p53 mediated apoptosis.
This gene is expressed primarily in infant brain and activated T-cells and to a lesser extent in bone marrow, fetal liver, and prostate.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, and tissue damage by radiation and anti-cancer drugs.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types {e.g., brain and other tissue of the nervous system, blood cells, bone marrow, liver, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to human Pig8 and murine EI24 genes indicate that polynucleotides and polypeptides corresponding to this gene are useful for preventing apoptosis in patients being treated with anti-oncogenic drugs such as etoposide, hydroperoxycyclophosphamide, and X-irradiation, since this protein product is upregulated in cells undergoing such treatment where p53 was overexpressed.
It may also be useful in the treatment of hematopoietic disorders and in boosting numbers of hematopoietic stem cells by interfering with the apoptosis of progenitor cells. The mature polypeptide is predicted to comprise the following amino acid sequence:
EEMADSV KTFLQDLARGIKDSIWGICTISKLDARIQQKREEQRRRRASSVLAQRRAQSIERKQES
EPRIVSRIFQCCAWNGGVFWFSLLLFYRVFIPVLQSVTARIIGDPSLHGDVWSWLEFFLTSIFSA
L W V LPLFV LS K V V NAI WFQDIADLAFE V SGRKPHPFPS V SKIIADMLFNLLLQALFLIQGMFV
SL
FPIHLVGQLVSLLHMSLLYSLYCFEYRWFNKGIEMHQRLSNIERNWPYYFGFGLPLAFLTAMQ
SSYIISGCLFSILFPLFIISANEAKTPGKAYLFQLRLFSLVVFLSNRLFHKTVYLQSALSSSTSAEK
FPSPHPSPAKLKATAGH (SEQ ID NO: 637). Accordingly, polypeptides comprising the foregoing amino acid sequence are provided as are polynucleotides encoded such polypeptides.
FEATURES OF PROTEIN ENCODED BY GENE NO: 115 This gene is expressed primarily in stromal cells and to a lesser extent in multiple sclerosis.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: affecting the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., stromal cells and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of multiple sclerosis and other autoimmune diseases.
r FEATURES OF PROTEIN ENCODED BY GENE NO: 116 This gene is expressed primarily in the gall bladder Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: gall stones or infection of the digestive system . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system or renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., gall bladder and tissue of the digestive system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for possible prevention of digestive disorders where there may be a lack of digestive enzymes produced or in the detection and possible prevention of gall stones.
FEATURES OF PROTEIN ENCODED BY GENE NO: 117 The translation product of this gene shares sequence homology with dystrophin gene which is thought to be important in building and maintenance of muscles.
This gene is expressed primarily in placenta and to a lesser extent in fetal brain and fetal liver, and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: muscular dystropy, Duchenne and Becker's muscular dystropies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal muscle system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, brain and other tissue of the nervous system, muscle, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the dystrophin gene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diseases related the degenerative myopathies that are characterized by the weakness and atrophy of muscles without neural degradation; such as Duchenne and Becker's muscular dystropies.
FEATURES OF PROTEIN ENCODED BY GENE NO: 118 This gene is expressed primarily in olfactory tissue and to a lesser extent in cartilage.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: connective tissue diseases; chondrosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., olfactory tissue and cartilage, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for tumors of connective tissues, osteoarthritis and the treatment and diagnosis of chondrosarcoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 119 This gene is expressed primarily in Activated Neutrophils and to a lesser extent in fetal spleen, and CD34 positive cells from cord blood.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: allergies, defects in hematopoiesis and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential r . ?..

identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and hematopoiesis system the, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and spleen, and cancerous and 5 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides 10 corresponding to this gene are useful for reducing the allergic effects felt by allergy suffers by neutralizing the activity of the immune system, especially since neutrophils are abundant in persons suffering from allergies and other inflammatory conditions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 120 15 The translation product of this gene shares sequence homology with poly A
binding protein II which is thought to be important in RNA binding for transcription of RNA to DNA
This gene is expressed primarily in colon and to a lesser extent in brain and immune system.
20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: colon cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a 25 number of disorders of the above tissues or cells, particularly of the immune and digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., colon, tissue and cells of the immune system, and brain or other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal 30 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to poly A binding protein II indicate that polynucleotides and polypeptides corresponding to this gene are useful for detection 35 and treatment of colon cancer and other disorders of the digestive system..

FEATURES OF PROTEIN ENCODED BY GENE NO: 121 The translation product of this gene shares sequence homology with thymidine diphosphoglucose 4.6 dehydrase which is thought to be important in the metabolism of sugar.
This gene is expressed primarily in fetal liver and spleen and to a lesser extent in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diabetes.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to thymidine diphospoglucose 4.6 dehydrase indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of persons with diabetes since it appears that this protein is needed in the metabolism of sugar in to its more basic components.
FEATURES OF PROTEIN ENCODED BY GENE NO: 122 The translation product of this gene shares sequence homology with ceruloplasmin which is thought to be important in the metabolism and transport of iron and copper. Ceruloplasmin also contains domains with homology to clotting factors V
and VIII. Defects in the circulating levels of ceruloplasmin (aceruloplasminemia) have been associated with certain disease conditions such as Wilson disease, and the accompanying hepatolenticular degeneration.
This gene is expressed primarily in brain and retina and to a lesser extent in endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases marked by defects in iron metabolism; aceruloplasminemia not characterized by defects in the r r known ceruloplasmin gene locus; nonclassical Wilson disease; movement disorders;
and tumors derived from a brain tissue origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of S the above tissues or cells, particularly of the brain, retina, and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, retinal tissue, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ceruloplasmin indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of patients with aceruloplasminemia, or other defects in iron and/or copper metabolism.
Mutations in this locus could also be diagnostic for patients currently experiencing or predicted to experience aceruloplasminemia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 123 This gene is expressed primarily in brain and B cell lymphoma and to a lesser extent in fetal liver and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: B cell lymphoma;
tumors and diseases of the brain and/or spleen; hematopoietic defects.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, blood cells, liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders in neuronal, WO 98!39448 PCT/US98/04493 hematopoietic, and immune systems. It could potentially be useful for neurodegenerative disorders and neuronal and/or hematopoietic cell survival or proliferation.
FEATURES OF PROTEIN ENCODED BY GENE NO: 124 This gene is expressed primarily in osteoclastoma, dermatofibrosarcoma, and B
cell lymphoma and to a lesser extent in endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer in particular osteoclastoma, dermatofibrosarcoma, and B
cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone, immune, and circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., bone, epidermis, blood cells, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers and lymphoma; osteoporosis; and the control of cell proliferation and/or differentiation.
FEATURES OF PROTEIN ENCODED BY GENE NO: 125 This gene is expressed primarily in immune tissues and hematopoietic cells, particularly in activated T cells and neutrophils, spleen, and fetal liver, and to a lesser extent in infant adrenal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects in T
cell activation; hematopoietic disorders; tumors of a hematopoietic and/or adrenal gland origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and/or endocrine systems, expression of this gene at significantly higher T

or lower levels may be routinely detected in certain tissues and cell types (e.g., cells and tissues of the immune system, hematopoietic cells, blood cells, liver, and adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune and/or hematopoietic disorders;
diseases related to proliferation and/or differentiation of hematopoietic cells; defects in T
cell and neutrophil activation and responsiveness; and endocrine and/or metabolic disorders, particularly of early childhood.
FEATURES OF PROTEIN ENCODED BY GENE NO: 126 This gene is expressed primarily in placenta and endothelial cells and to a lesser extent in melanocytes and embryonic tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors of an endothelial cell origin; angiogenesis associated with tumor development and metastasis.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system and developing embryo, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endothelial cells, melanocytes, and embryonic tissues, and cancerous and wounded tissues) or bodily fluids {e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of developmental disorders;
inhibition of angiogenesis; and vascular patterning.
FEATURES OF PROTEIN ENCODED BY GENE NO: 127 This gene is expressed primarily in endothelial cells and hematopoietic tissues, including spleen, tonsils, leukocytes, and both B- and T-cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors of an endothelial cell and/or hematopoietic origin; leukemias and lymphomas. Similarly, polypeptides 5 and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and vascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endothelial cells, hematopoietic cells, spleen, 10 tonsils, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
15 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the manipulation of angiogenesis;
the differentiation and morphogenesis of endothelial cells; the proliferation and/or differentiation of hematopoietic cells; and the commitment of hematopoietic cells to distinct cell lineages.
FEATURES OF PROTEIN ENCODED BY GENE NO: 128 This gene is expressed primarily in kidney medulla and to a lesser extent in spleen from chronic myelogenous leukemia patients, prostate cancer, and some other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors of a kidney origin; chromic myelogenous leukemia; prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the kidney and spleen, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., kidney, spleen, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
T r The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of kidney disorders and cancer, particularly chromic myelogenous leukemia and prostate cancer.
It may also be useful for the enhancement of kidney tubule regeneration in the treatment of acute renal failure.
FEATURES OF PROTEIN ENCODED BY GENE NO: 129 This gene is expressed primarily in adult and infant brain and to a lesser extent in mesenchymal or fibroblast cells, as well as tissues with a mesenchymal origin.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors of a brain andlor mesenchymal origin; neurodegenerative disorders; cancer; fibrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and of mesenchymal cells and tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of tumors of a brain and/or mesenchymal origin; neurodegenerative disorders; cancer; and fibrosis, based upon the expression of this gene within those tissues. Fibrosis is considered as mesenchymal cells and fibroblasts are the primary cellular targets involved in this pathological condition.
FEATURES OF PROTEIN ENCODED BY GENE NO: 130 This gene is expressed primarily in hepatocellular cancer and to a lesser extent in fetal tissues as well as testes tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: liver cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, fetal tissue, and testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 131 This gene is expressed only in infant early brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: development and diseases of the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the brain in children and in treating nervous system disorders such as Alzheimer's disease, schizophrenia, dementia, depression, etc.
FEATURES OF PROTEIN ENCODED BY GENE NO: 132 This gene is expressed primarily in brain and to a lesser extent in glioblastoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Alzheimer's disease, schizophrenia, depression, mania, and dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating brain.disorders such as Alzheimer's disease, schizophrenia, depression, mania, and dementia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 133 The translation product of this gene shares sequence homology with ribitol dehydrogenase of bacteria which is thought to be important in metabolism of sugars.
This gene is expressed primarily in macrophage and to a lesser extent in T-cell lymphoma and lung.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tissue deswction in inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ribitol dehydrogenase indicate that polynucleotides and polypeptides corresponding to this gene are useful for altering macrophage metabolism in diseases such as inflammation where macrophages are causing excess tissue destruction.

FEATURES OF PROTEIN ENCODED BY GENE NO: 134 This gene is expressed primarily in pancreatic tumor and to a lesser extent in synovial sarcoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and connective tissue systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pancreas, and synovial tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing various cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 135 This gene is expressed primarily in T cell lines such as Raji and to a lesser extent in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune system disorders and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing inflammatory diseases r such as rheumatoid arthritis, sepsis, inflammatory bowel disease, and psoriasis, as well as neutropenla.
FEATURES OF PROTEIN ENCODED BY GENE NO: 136 5 The translation product of this gene shares high sequence homology with SAR

subfamily of GTP-binding proteins which is thought to be important in vesicular transport in mammalian cells.
This gene is expressed primarily in serum-stimulated smooth muscle cells and to a lesser extent in a T-cell lymphoma.
10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: diseases affecting vesicular transport. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing imrnunological probes for differential identification 15 of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample 20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to GTP-binding proteins indicate that polynucleotides and polypeptides corresponding to this gene are useful for gene therapy 25 in treating the large number of diseases involved in defective vesicular transport within cells..
FEATURES OF PROTEIN ENCODED BY GENE NO: 137 The translation product of this gene shares sequence homology with a protein 30 found in C. elegans cosmid F25B5.
This gene is expressed primarily in a fetal tissues and to a lesser extent in rnelanocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a 35 biological sample and for diagnosis of diseases and conditions: abnormal fetal development, especially of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissue, pulmonary tissue, and melanocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases affecting the pulmonary system, such as emphysema.
FEATURES OF PROTEIN ENCODED BY GENE NO: 138 This gene is expressed primarily in gall bladder and to a lesser extent in smooth muscle.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: digestive system disease and gall bladder problems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., gall bladder and tissue of the digestive system, and smooth muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the digestive system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 139 This gene is expressed primarily in placenta and to a lesser extent in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue{s) or cell types) present in a biological sample and for diagnosis of diseases and conditions: abnormal fetal development. Similarly, polypeptides and antibodies directed to these polypeptides are ~, fi useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developing tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing abnormal fetal development.
FEATURES OF PROTEIN ENCODED BY GENE NO: 140 This gene is expressed primarily in smooth muscle and to a lesser extent in ovary, prostate cancer, and activated monocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: hypertension and atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., smooth muscle, ovary and other reproductive tissue, prostate, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases of the circulatory system, such as hypertension, atherosclerosis, etc.
FEATURES OF PROTEIN ENCODED BY GENE NO: 141 This gene is expressed primarily in fetal spleen and to a lesser extent in placenta and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: anemia and other - diseases affecting blood cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and pulmonary systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., spleen, placenta, bone marrow, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the generation of red and white blood cells and for the diagnosis of disease of these cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 142 The predicted translation product of this contig is a human homolog of the marine tetracycline/sugar transporter molecule recently reported by Matsuo and colleagues (Biochem. Biophys. Res. Commun. 238 (1), 126-129 (1997)).
This gene is expressed primarily in synovium and to a lesser extent in endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: rheumatoid arthritis and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and lymphatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., synovial tissue, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
r r The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammatory diseases, such as rheumatoid arthritis, leukemia, neutropenia, inflammatory bowel disease, psoriasis, sepsis, and the like.
FEATURES OF PROTEIN ENCODED BY GENE NO: 143 This gene is expressed primarily in placenta and to a lesser extent in melanocyte, fetal liver and spleen, and bone marrow.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: abnormal early development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, melanocytes, liver, spleen, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of abnormal early development phenomena and diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 144 This gene is expressed primarily in fetal liver and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: anemia and neutropenia.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and blood systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful in hematopoeisis and bone marrow regeneration 5 as it is most abundant in fetal tissues responsible for the generation of hematopoeitic cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 14S
The translation product of this gene shares sequence homology with protein 10 tyrosine phosphatase which is thought to be important in transducing signal to activate cells such as T cell, B cell and other cell types.
This gene is expressed primarily in T cells and tissues in early stages of development and to a lesser extent in cancers.
Therefore, polynucleotides and polypeptides of the invention are useful as 15 reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immuno-related diseases and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, 20 particularly of the immune system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types {e.g., embryonic and fetal tissue, undifferentiated cells, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to 25 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the protein tyrosine phosphatase family indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating the immune system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 146 This gene is expressed primarily in T cell and to a lesser extent in B cell, macrophages and tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell type{s) present in a biological sample and for diagnosis of diseases and conditions: immuno-disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in r providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating the immune system therefore can be used in treating diseases such as autoimmune diseases and cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 147 This gene is expressed primarily in placenta and to a lesser extent in endothelial cells, testis tumor, ovarian cancer, uterine cancer.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not linuted to cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endothelial cells, testis and ovary and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 148 This sequence has significant homology to mouse torsin A. Recently, another group cloned the human Torsin A gene. (See, Accession No. 2358279; see also Nature Genet. 17, 40-48 ( 1997).) This gene is expressed primarily in osteoclastoma, T-cell, and placenta and to a lesser extent in fetal lung, fetal liver, fetal brain, adult brain and tumor tissues Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: disease conditions in hematopoiesis and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoiesis system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, bone, placenta, lung, liver, and brain and other tissues of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating blood related diseases such as deficiencies in red blood cell, white blood cell, platelet and other hematopoiesis cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 149 This gene is expressed primarily in T cell, prostate and prostate cancer, endothelial cells and to a lesser extent in monocyte, dendritic cell, bone marrow, salivary gland, colon cancer, stomach cancer, pancreatic tumor, uterine cancer, fetal spleen and osteoclastoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immuno-related diseases and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, prostate, endothelial cells, dendritic cells, bone marrow, salivary gland, colon, stomach, pancreas, uterus, spleen and bone, and cancerous and wounded tissues) or bodily fluids (e.g.> serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
r The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 150 This gene was recently cloned by another group, calling it eIF3-p66. (See Accession No. 2351378.) This gene plays a role in RNA binding and macromolecular assembly, and therefore, any mutations in this gene would likely result in a diseased phenotype. Preferred polypeptide fragments comprise the amino acid sequence:
MAKFMTPVIQDNPSGWGPCAVPEQFRDMPYQPFSKGDRLGKVADWTGATYQDKRYTNKYSS
QFGGGSQYAYFHEEDESSFQLVDTARTQKTAYQRNRMRFAQRNLRRDKDRRNMLQFNLQILP
KSAKQKERERIRLQKKFQKQFG VRQKWDQKSQKPRDSS VE VRS DWEV KEEMDFPQLMKMRY
LEVSEPQDIECCGALEYYDKAFDRITTRSEKPLRXXKRIFHTVTTTDDPVIRKLAKTQGNVFATD
AILATLMSCTRS V YS WDIV V QRV GS KLFFDKRDNSDFDLLTVSETANEPPQDEGNSFNSPRNL

EHDGVMTGANGEVSFINIKTLNEWDSRHCNGVDWRQKLDSQRGAVIATELKNNSYKLARWTC
CALLAGSEYLKLGYVSRYHVKDSSRHVILGTQQFKPNEFASQINLSVENAWGILRCVIDICMKL
EEGKYLILKDPNKQVIRVYSLPDGTFSS (SEQ ID NO: 638), as well as N-terminal and C-terminal deletions of this polypeptide fragment.
This gene is expressed primarily in T cell, bone marrow, embryo and endothelial cells and to a lesser extent in testis tumor and endometrial tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune diseases and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders and cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 151 This gene is expressed primarily in testis and to a lesser extent in T cell, spinal cord, placenta, neutrophil and monocyte.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: male reproductive and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testis and other reproductive tissue, blood cells, tissue of the nervous system, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating immune and reproductive functions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 152 The translation product of this gene shares sequence homology with tyrosyl-tRNA synthetase which is thought to be important in cell growth.
This gene is expressed primarily in brain, liver, keratinocytes, tonsils, and heart.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, keratinocytes, tonsils, heart expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissues of the nervous system, liver, keratinocytes, tonsils and heart, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to tyrosyl-tRNA synthetase indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating 5 cell growth.
FEATURES OF PROTEIN ENCODED BY GENE NO: 153 This gene is homologous to the Drosophila transcriptional regulator dre4. (See Accession No. 2511745.) Dre4 is a gene required for steroidogenesis in Drosophila 10 melanogaster and encodes a developmentally expressed homologue of the yeast transcriptional regulator CDC68. Preferred polypeptide fragments comprise the amino acid sequence: KKRHTDVQFYTEVGEITTDLGKHQHMHDRDDLYAEQMEREMRHKLKTAFKN
FIEK V EALTKEELEFEV PFRDLGFNGAPYRSTCLLQPTS SAL V NATEWPPFV VT'LDEVELIHFXR
VQFHLKNFDM V IV YKDYSKKVTMINAIPV ASLDPIKEWLNSCDLKYTEG V QSLNWTKIMKTIV D
15 DPEGFFEQGGWSFL (SEQ ID NO: 639), as well as N-terminal and C-terminal deletions of this fragments. Also preferred are polynucleotide fragments encoding this polypeptide fragment.
This gene is expressed primarily in fetal liver, spleen, placenta, lung, T
cell, thyroid, testes.
20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: brain tumor, heart and liver diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) 25 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal liver, spleen, placenta, lung, T cell, thyroid, testes expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, spleen, placenta, lung, blood cells, thyroid, and testes and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, 30 plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 154 This gene is expressed primarily in brain and to a lesser extent in fetal heart, testis, spleen, lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: heart, liver and spleen diseases, immunological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, fetal heart, testis, spleen, lung expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, heart, testes and other reproductive tissue, spleen, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 155 Activation of T cells through the T cell antigen receptor (TCR) results in the rapid tyrosine phosphorylation of a number of cellular proteins, one of the earliest being a 100 kDa protein. This gene is the human equivalent of murine valosin containing protein (VCP). VCP is a member of a family of ATP binding, homo-oligomeric proteins, and the mammalian homolog of Saccharomyces cerevisiae cdc48p, a protein essential to the completion of mitosis in yeast. Both endogenous and expressed murine VCP are tyrosine phosphorylated in response to T cell activation. Thus we have identified a novel component of the TCR mediated tyrosine kinase activation pathway that may provide a link between TCR activation and cell cycle control.
This gene is expressed primarily in brain, liver, spleen, placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue{s) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, spleen, placenta expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, spleen, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from t an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to VCR indicate that polynucleotides and polypeptides corresponding to this gene are useful for treating cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 156 The translation product of this gene shares sequence homology with rat growth response protein which is thought to be important in cell growth. A group recently cloned the human homolog of this gene, calling it insulin induced protein 1.
(See Accession No. 2358269, see also, Genomics 43 (3), 278-284 ( 1997).) Preferred polypeptide fragments comprise the amino acid sequence: RSGLGLGTI'IAFi.ATLITQF
LVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMGVPEKPHSD (SEQ ID NO: 640), as well as N-terminal and C-terminal deletions of this polypeptide fragment.
Also preferred are polynucleotide fragments encoding these polypeptide fragments.
This gene is expressed primarily in brain, liver, placenta, heart, spleen, lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, liver, placenta, heart, spleen.
expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, placenta, heart, spleen, and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to growth-response protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for modulating cell growth.

FEATURES OF PROTEIN ENCODED BY GENE NO: 157 This gene is expressed primarily in Glioblastoma, endometrial tumor, lymphoma and pancreas tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Glioblastoma, Endometrial tumor, lymphoma and pancreas tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, lymphoid tissue, pancreas, and tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids {e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 158 The translation product of this gene shares sequence homology with IGE
receptor which is thought to be important in allergy and asthma.
This gene is expressed primarily in T cell, and fetal liver.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: allergy and asthma and other immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to IgE receptor indicate that polynucleotides and polypeptides corresponding to this gene are useful for allergy and asthma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 159 The translation product of this gene shares sequence homology with immunoglobin heavy chain which is thought to be important in immune response to the antigen.
This gene is expressed primarily in activated neutrophil and to a lesser extent in activated T cell, monocyte and heart.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: infection , inflammation and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, and heart, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to immunoglobin heavy chain variable region indicate that polynucleotides and polypeptides corresponding to this gene are useful for making the ligand to block specific antigen which cause certain disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: 160 The translation product of this gene shares sequence homology with mouse X
inactive specific transcript protein which is thought to be important in X
chromosome inactivation.
This gene is expressed primarily in HSA 172 cell and to a lesser extent in normal ovary tissue, ovarian cancer, frontal cortex and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: ovarian tumor, schizophrenia and other neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovary and other reproductive tissue, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to X inactive specific transcript protein indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of reproductive system tumors and CNS tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 161 This gene is expressed primarily in adipose cell and to a lesser extent in liver and prostate.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: obesity and liver disorder. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adipose cell, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., adipose cells, liver, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level> i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of obesity and liver disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: lb2 The translation product of this gene shares sequence homology with yeast ubiquitin activating enzyme homolog which is thought to be important in protein posttraslation processing.

This gene is expressed primarily in stromal cell and to a lesser extent in retina, H. Atrophic Endometrium, colon carcinoma and myeloid progenitor cell.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: defects of stromal cell development, neuronal growth disorders and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., retinal cells, endometrium, colon, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ubiquitin-activating enzyme homolog indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of some type of tumors , fucosidosis and neuronal growth disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 163 This gene is expressed primarily in primary breast cancer and hemangiopericytoma and to a lesser extent in adult brain and cerebellum.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: breast cancer, leukemia and cerebellum disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and neural system , expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of various tumors and disease involved in neural system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 164 The translation product of this gene shares sequence homology with proline rich proteins. Recently, another group has also cloned this gene, calling it CD84 leukocyte antigen, a new member of the Ig superfamily. (See Accession No. U82988, see also, Blood 90 (6), 2398-2405 ( 1997).) This gene is expressed primarily in Weizmann olfactory tissue and osteoclastoma and to a lesser extent in anergic T-cell.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: ostsis and immune disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., olfactory tissue, bone, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy-tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the Ig superfamily indicate that the protein product of this clone is useful for treatment of osteoporosis, autoimmune disease, and other immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 165 This gene is expressed primarily in atrophic endometrium and colon cancer and to a lesser extent in some fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: tumors.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, T

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., endometrium, colon, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumors, specifically endometrium and colon tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 166 This gene is expressed primarily in human primary breast cancer and to a lesser extent in activated monocyte. Although the predicted signal sequence is identified in Table 1, other upstream sequences are also relevant. Preferred polypeptide fragments comprise the amino acid sequence: VTQPKHLSASMGGSVEIPFSFYYPWELAXXPXVRISWRRGHFHG
QSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQSVYFCRVELDTRRSG (SEQ ID
NO: G41 ), as well as N-terminal and C-terminal deletions. Also preferred are polynucleotide fragments encoding these polypeptide fragments.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: breast cancer.
Similarly, polypeptides and antibodies directed to these poiypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of breast cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 167 This gene is expressed primarily in fetal tissues and to a lesser extent in adult lung. This gene has also been mapped to chromosomal location 9q34, and thus, can be used as a marker for linkage analysis for chromosome 9.

WO 98/39448 PCTlUS98/04493 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue{s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the embryo tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., fetal tissues, and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 168 The translation product of this gene shares sequence homology with Ig Heavy Chain which is thought to be important in immune response.
This gene is expressed primarily in prostate cancer tissue specifically Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue{s) or cell types) present in a biological sample and for diagnosis of diseases and conditions: prostate cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate, tissue and cells of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 169 The translation product of this gene shares sequence homology with cytosolic acyl coenzyme-A hydrolase, which is thought to be important in neuron-specific fatty acid metabolism. The gene represented by this contig has since been published by Hajra and colleagues (GenBank Accession No. U91316).
r. T

This gene is expressed primarily in human pituitary gland and to a lesser extent in colorectal cancer tissue. This gene has also been observed in the LNCAP
cell line.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell type{s) present in a biological sample and for diagnosis of diseases and conditions:
hyperlipidemias of familial and/or idiopathic origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly blood, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., pituitary and colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to rat cytosolic acyl coenzyme-A
hydrolase indicate that polynucleotides and polypeptides corresponding to this gene are useful for the detection or treatment of hyperlipidemia disease states by virtue of the ability of specific drugs to activate the enzyme.
FEATURES OF PROTEIN ENCODED BY GENE NO: 170 The translation product of this gene shares sequence homology with a Caenorhabditis elegans gene which is thought to be important in organism development.
This gene is expressed primarily in human synovial sarcoma tissue, bone marrow, and to a lesser extent in human brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, of bone, specifically synovial sarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone, connective tissues and possibly immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., synovial tissue, bone marrow, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to Caenorhabditis elegans indicate that polynucleotides and polypeptides corresponding to this gene are useful as a diagnostic and/or therapeutic modality directed at the detection and/or treatment of connective tissue sarcomas or other related bone diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 171 The translation product of this gene shares sequence homology with betal-6GlcNAc transferase which is thought to be important in the transfer and metabolism of betal-6, N-acetylglucosamine. This gene product has previously been shown to suppress melanoma lung metastasis in both syngeneic and nude mice, decreased invasiveness into the matrigel, and inhibition of cell attachment to collagen and laminin without affecting cell growth.
This gene is expressed primarily in human testes and prostate tissues, and to a lesser extent in kidney, medulla, and pancreas.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer particularly melanoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., testes and other reproductive tissue, prostate, kidney, pancreas, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to betal-6GlcNAc transferase indicate that the protein product of this clone is useful for the development of diagnostic and/or therapeutic modalities directed at the detection and/or treatment of cancer, the metastasis of malignant tissue or cells. Defects in this potentially secreted enzyme may play a role in metastasis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 172 This gene is expressed primarily in fetal spleen and liver, Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: immune disorders, Wilm's tumor disease, hepatic disorders, and hematopoietic disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoiesis and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., spleen and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and identification of fetal defects along with correcting diseases that affect hematopoiesis and the immune system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 173 The translation product of this gene shares sequence homology with ret II
oncogene which is thought to be important in Hirschsprung disease and many types of cancers.
This gene is expressed in multiple tissues including the lymphatic system, brain, and thyroid.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: Hirschsprung disease and multiple cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lymphoid tissue, thyroid, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ret II oncogene indicate that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of various cancers. It would also be useful for the diagnosis and treatment of Hirschsprung disease. Preferred polypeptides of the invention comprise the amino acid sequence: MEAQQVNEAESAREQLQXLHDQIAGQKASKQELETELERLKQEFHYIEEDLY
RTKNTLQSRIKDRDEEIQKLRNQLTNKTLSNSSQSELENRLHQLTETLIQKQTMLESLSTEKNSL
VFQLERLEQQMNSASGSSSNGSSINMSGIDNGEGTRLRNVPVLFNDTETNLAGMYGKVRKAAS
SIDQFSIRLGIFLRRYPIARVFVIIYMALLHLWVMIVLLTYTPEM HHDQPYGK (SEQ ID NO:
642).
FEATURES OF PROTEIN ENCODED BY GENE NO: 174 The translation product of this gene shares sequence homology with testis enhanced gene transcript which is thought to be important in regulation of human development.
This gene is expressed primarily in infant brain and to a lesser extent in a variety of other tissues and cell types, including the prostate, testes, monocytes, macrophages, dendritic cells, keratinocytes, and adipocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neurological, developmental, immune and inflammation disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, prostate, testes and other reproductive tissue, blood cells, keratinocytes, and adipocytes, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to testis enhanced gene transcript indicate that the protein product of this clone is useful for diagnosis and treatment of disorders involving the developing brain and the immune system.
r t09 FEATURES OF PROTEIN ENCODED BY GENE NO: 175 This gene is expressed primarily in prostate and to a lesser extent in various other tissues, including placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, especially of the prostate. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., prostate and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is useful for diagnosis and treatment of prostate disorders and cancer. It may also be useful for the diagnosis and treatment of endocrine disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 176 The translation product of this gene shares sequence homology with Sacchromyces cerevisiae YNT20 gene which is thought to be important in mitochondrial function.
This gene is expressed at a particularly high level in muscle tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases related to such tissues and cell types including: muscle wasting diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., muscle and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to the YNT20 gene indicate that this protein is useful for treatment and detection of neuromuscular diseases caused by loss of mitochondria) function. For example this gene or its protein product could be used in replacement therapy for such diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 177 This gene is expressed primarily in the brain and to a lesser extent in kidney, placenta, smooth muscle, heart and lung.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: neuromuscular diseases, degenerative diseases of the central nervous system, and heart disease.
1 S Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, central nervous system, and heart, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, kidney, placenta, muscle, heart and lung, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
This gene or its protein product could also be used for replacement therapy for the above mentioned diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 178 The translation product of this gene shares sequence homology with caldesmon which is thought to be important in the cellular response to changes in glucose levels.
This gene is expressed primarily in multiple tissues including brain and retina.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: central nervous system disorders and retinopathy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for identification of the tissues) or cell T

type(s). For a number of disorders of the above tissues or cells, particularly of the CNS
disorders and retinopathy, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, and retinal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to caldesmon indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of retinopathies.
FEATURES OF PROTEIN ENCODED BY GENE NO: 179 The translation product of this gene shares sequence homology with mouse fibrosin protein which is thought to be important in regulation of fibrinogenesis in certain chronic inflammatory diseases.
This gene is expressed primarily in amniotic cells and breast tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of breast cancer and abnormal embryo development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., amniotic cells, and mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to fibrosin indicate that the protein product of this clone is useful for treatment of breast cancer. This gene or its protein product could be used in replacement therapy for breast cancer. In addition the protein product of this gene is useful in the treatment of chronic inflammatory diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 180 This gene is expressed several infant tissues including brain and liver and various adult tissues including brain, lung, liver, testes, and prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain cancer, lung cancer, liver cancer and cancers of the reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, hepatic system, and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, lung, liver, testes and other reproductive tissue, and prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution of this gene product indicates that the protein product of this clone is involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 181 This gene is expressed primarily in activated monocytes and to a lesser extent in melanocytes and dendritic cells.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of immune system diseases and cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, melanocytes, and dendritic cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone could be involved in growth regulation and could be used as a growth factor or growth Mocker in a variety of settings including treatment of cancers.
r FEATURES OF PROTEIN ENCODED BY GENE NO: 182 This gene is expressed primarily in placenta and several tumors of various tissue origin and to a lesser extent in normal tissues including liver, lung, brain, and skin, Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of cancers of all kinds. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, respiratory system and skin, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types {e.g., liver, lung, brain and other tissues of the nervous system, and skin, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The high expression of this gene in multiple tumors indicates that the protein product of the clone may be involved in cell growth control and therefore would be useful for treatment of certain cancers. Likewise molecules developed to block the activity of the protein product of this clone could be used to block its potential role in tumor growth promotion.
FEATURES OF PROTEIN ENCODED BY GENE NO: 183 The translation product of this gene shares sequence homology with the mouse Ndr I gene which is thought to be important in cancer progression.
This gene is expressed multiple cell types and tissues including brain, lung, kidney, bone marrow, liver, and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of all types of cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous, immune, and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, lung, kidney, bone marrow, liver and spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to Ndrl gene, which is thought to be involved in cancer progression, indicate that polynucleotides and polypeptides corresponding to this gene are useful for treatment of certain cancers.
Likewise molecules developed to block the activity of the protein product of this clone could be used to block its potential role in tumor growth promotion.
FEATURES OF PROTEIN ENCODED BY GENE NO: 184 This gene is expressed primarily in early stage human brain and liver and to a lesser extent in several other fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as 1 S reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of diseases and conditions: brain and liver cancers.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, liver, and fetal tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 185 This gene is expressed primarily in infant and embryonic brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of degenerative nervous system disorders and brain cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell T

type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., embryonic tissue, brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 186 This gene is expressed primarily in multiple tissues including placenta, fetal lung, fetal liver, and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissues) or cell types) present in a biological sample and for diagnosis of all types of cancers including liver, brain and lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissues) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, pulmonary system, and hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, lung, liver, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
The expression of this gene in embryonic tissues indicates that the protein could be involved in growth regulation and could be used as a growth factor or growth blocker in a variety of settings including treatment of cancers.

O O N N N M N N
.r O ,_, O N 0. O~ Ov M N N
~'' 00 00 O
o ~ o M ~' M ~ M V7 z ~ ~. O ~ ~ I~ ~ p'-"p O~ ~' M
~L ~~ d' z o ~b ~ N

U
E..,. ~ Q, N o ~ M ~t ~' z ~ p ~ 00 M ~D

M
z o o ~ ~, ~ .-. N ~"
~n U ~ N N

.n I~ ~ M
z d ~ O ~ .--~ N Ov ..., O
L~.v L
Q Q Q d ti W
N N
y ~ ~ M ~ I~ ~ M Q~ t~ ~ M OWE O~ ~ O~ l~ O~ ~ O~ l~ ~ ~ Q~
U~oN '° ~'~o n °'~o n °'~o n °'~o~n °Wco~n °'~o n ~' ~zb ~N~~~N~~~N~o~o°o~o°o O N O O N O O N N O
N N
Q~ N N
z ~ w w cA as u., w a "U
o x x ~ x x x N N M M
~z r r ~

N t M 00 N
~1 a ~ ~ _ b~O~"'~ M ~

N N cY N
i. ~ O

H

w b_p L1, .-O Cn M 00 N N N

Gr w GU N, N ~

O ~ . ~ .-~ .--~ .-.i .., ~r O

N
M M M M M M

w ~
~
~

.~. f3w N Q1 ~
w ~ O
~
.'~

~ 0, N N

G
z N O M 1~~
~ b ~ ~-~ M N N r' C/~ U

,~,, G p~ 00 M_ ~O '~ U O

N vD cVi d' d' ~n zo o ""

~r M ~ ~r o, o M

z~~o~c a W W W W >Q

N

N N N N

y U'~N s ~~~~ ~~~~ ~~~~ ~oyo. ~ay~, ~~~~

Ll ~~o~n yoo~n ~~o~n yoom ~ 00 a ( Ov N CT N ~ N ~ N ~ N ~ N
z ~ ~ ~ ~ ~ ~ V\1 ~ N ~ V1' j ~ O O O O ) y O p p O O O O O

N . --. O ~ M
~

a a > Q ~
x 00 ~ ~ ~ ~ a ~ ""' " U x x x x x x z w ~ v-, ~ ~r o, ' a ov O v D --~ ~ N

O . ~ N

.b ~
~
v _ r... . -.
w ~ 01 M M
~

~~' ~ G, ~ 00 ~ O

0 ~ .
w b _ ~ ~ , .
0 ., w ~ Q.

N
~

O O
t1 O
' Oy y 0 p z o ~ ~ ~ o ~ O
U

p ~ ~ M M
z o o M I~- ~ ~ V1 M "~

Z w C Q' v~ ., N r..

O O N ~ v~ ~ N

~n U ~

'~ E~ a' ~" -" ~ ~ oho z~ M
~

, , ..., --~ N N
~'~ ~ ~C O O N O N O
Z

O

Q Q d O CL
p, N N N N

a a N t~ (~ C~~ h l'~ I~ C~ I~ M I~ M
U'~N s ~ov.~ l~ ~a'~' ~'~a' I~ l~
' ~o'~o' ~'~t' ~oyov G~ ~no~ wootn ~o~ ~o~n ~o~n mom U o b ~' ~ ) N ~ ~ N O~ N
~ \' v7 ~ ~ ~ ~

N ~ N ~ O~ N O~ ~ O O O
V V y O

O O O O O O

G~ o x x ~ ~ Q Q

w ~ z z w w x x x x x x ~ ~ o y~7 N ~n o 0 00 ~ err' O N y. ~-~ N vp M 00 M M N N M

'~
0..
C/

u.
~

4~ CQ Q. _ O C%~ N OM M N N
~

p ,r O O O N O

r c~

O ~ O p O O

~ ~ ~ p ~ N O
w G
.b N I~ O ~ M

O o N o 0 O ~ ~ N M

~t ~ ~ M O N

M - N

M

O ~ a~ ~ ~-~ r. V7 O ~' ~ "' .,..., v'~ U _.., O" 00 ~ M 00 d' ~ M M M
C~ -, ~ ~ ~D

, .--~N .-.

'X N O O
' z~~

~, O
, N N

' N N N N N
~

..., G ~~ p C C G C

N h C"~ (~ l'~ (~. l',-~ i~ (T t"'. l~ ~ I~ Q~ I~ Q~ ~~-M Q1 Q~ l~ pv ~ M O~ M Qy p~
~' M O~ M Ov ~tw '~T- M pv ~ ' d' p (~ 1 ~~0~ 1 N~ "" ~~ ~,,~
~~Ov ~~OV ~ ~ w o ~ N ~ N ~O O
0 ue O
O' f-' ~ z '.d ' v ~ N ' G~ y O I\
~ ~ W ~ y w .. y y N~~
N Ov Ov ~ C ~ N ~
Ov N ~ V1 ~ cT cT O~ v1 ~ ~n O~ ~ yn 0 ~ O
~ v~

O N N O ( N y O O O

O O O O O O O O

d- ~ ~Y ~p >

~ ~ ~ ~ a x ~ x O M M M M ~' d' WO 98!39448 PCT/LTS98/04493 w ~ pW p M N V1 M
O ~ M ~ M M N

O

Q ~ C
d ~n o N

w Ov ..~ ~., N N N
. -~ N M M
b ~ O V ~

c~ ~ ~ O

ur w bA Q.

L ~ ~ ~ ~ r1 r-1 ~ rl ~--1 rl ~~~o~. O N N ~ OM M

M M ~ M M

~ d' O ~D

~ vD N M M
CL W
~

~

O t~ ~ ~O

'Z O
~

O V~ N M M
U
N

M

zoos- N ~ N

W U~

Q" ~ ~ t~ c~ ~n z /~ ~ r~ ~ N N ~ N N

Q Q Q ~ Q a N N N N N N

U ~N ~ ~'~'Q' ~~' ~~.~'s ~'.~' ~o'MVs ~~~~

U L1 ~ ~ ~o~n ~ov~ ~o~n ~o~n vo~~n mow Z"O ~NO~ ~NO~ ~ ~NO~ ~NOv~1 ~NO~
~NO i N NO v NO NO ONO

NO

O O O O O
O

~O M O

z~ '~ w ~ ~ ~ a ~

coo ~ x o o o ~

x x x x x O ~ N O ~ N

O .....~

O ~ _. _ ~

~ ~p .--, oo N .-~ ~D
U Q ,,."
a .O

%b ~ O ~-' M M N N M N
~

4_-' N 4Y

'~ ~,,_, bD t3. M M N N ~ N
O ~ ~

H

w ~ G

N M -_ ~ v7 N_ M M t!1 M M ~!'~

O ~

b_O O l~ 00 ~ M 00 ~ M
~

C~

O f'~ h ~O
~
z o ~

z M ~ M
o o a, z o o N

in U ~

E~ a' z~
~

, ~ O

c N M M
rt ~r O ~C

Q
N

~ ~ ~ N N

c. a. U y y U'~N ~ ~o~~' ~a'MV' ~a'~' ~Q'~' ~a'~' ~o,''''o~
~'~

U o Ll oo~o~n oO~co~nyoo~n ~~o~n ~~aov~~
~n ~ cV p~1 ~ ~ Q\ N O~ G~ N
y j N ~ ~ i ~ ~n N 'C~'N
t j ~ V'1 ~n O O O O O O O O O O O O

c~ O O

w w a ~ ~

U U O O O

U

x x x x x x a~ _ _ ON N N N N N

~' ~
O

a ~' ef' M ~ M
Q O

w ~ v .-~ .-. v~ .~ .-. ~.

%Zj ~ O ~-' M M N N M N
~

N 4_..~ ~
O

~~w O O N O O O

p ~ M

~ M M r. ~-~ M
~0,~'"

w O

C ~. ~ 01 N I' ~ O
z "-' s.'i'..

O ..: dp 00 .-.r l~ M - N
C~

O vp v~
z ~

o ~ ~, ~ M

~

M ~ M o 0 f O~ V1 ~O V~ M

H
z w ~ -~ -.
~' p ..-~ .-, .~ . .
O ~, 'v~

~ H ~"
M

~ ~ ~ ~ ~
z~

, , N
M M

M N N M

Q" ~, ~ ~ ~ r O U GL G, ~. fy G-i N N N N N

c~

.
a ~ ~ ~ ~ ~ c~ ~ ~. ~ ~. r t-U'~N i ~o~ oo~~ov oooyo~ ooo,~o~~ oooyo~
~ ooo~~~

U o p ~ ~~om ~~o~n ~ oo~n yoo~n yoo~n ~~om zb ~ ~N ~ ~ j i ~N~V' i ~ j ~
l Q~ N~~ yn ~ yn c 1 O yN O
O

O O O O O O O O O

N ~ 41 00 00 o ~

y N
z ~ z w w w w ~ W W W W a V r n x x x x x x N N N N N N

WO 98!39448 PCT/US98/04493 N ~O ~O ~ M O
' ~

J O ct N N V

Q

..-~ O_ _ _ a O ~ ~~ M N N M N

U

~
~

~ w ~-0 ~ 00 O N ~ N

~ M N .-.
O ~ ~

~_~ ~

w N N O ~t' N M
~

~ w M ~i' t,-O
O N O~ I~ h l~

p ~ U N O ch N~ N

z o o m N
M cT

O O ~ .-, M ~n O
~n ~n U ~

CT N O ~ ~

O
' , o ' N N
O

~ M ~ V

x x x x ~ ~ ~ ~ x o ~ o~ ~ ~ ~ ~, j N N " ' " N
a o a . . , y ~rn~o~ o~~Q. oyv~ ~~~o~ ~

U oovo ~ oo~ ~ ~ ~~ov~ ~
L1 yoov~ ~~ov, y0 o ~ O ~ ~'' O 1 O v ~
z ~ ~ O ~ ~ O ~
~

Q C~ N N N V N N N
~ N O O
~

O O O O O O O O O O

M

Q x U

L7 > ~ ~ ~ W

UU x x x x x a~
O O 00 Q\ O ~-~ ~' N
U

Z N N M M M M

M ~ 1 M ~ ~

O N

~a O M

:b a p V ~ .-. O~ N M
~j~,-' M .-.

N i_, ~ O
Ar ~

a ~ c,.., Ov O o~0 O~
~0 ~ M
O ~

~

N

' o~ ~ ~ ~ h V1 M M ~ M

z w. 4 o o. ~r M
~ o M

~ o .-, h ~ o0 o f ~ G.~

~n i.

z w. ~ b Wit' o ....~

p U h 00 h ~ M ~ G\

O U1 d' M

z~.~~-N

00 00 h h ~O .--~ ~' O~ .-, Z ~ M

~ M ~r ' C/7 j ~ d j ~' N

O (3. f~. 0.. GL O. C.

N N N N N N

a h h h h h U O ~ ~ ~p ~ ~p yo o ~ ~p yc o yp o ~ ~n o ~n ~n o v~ ~n ~n O Z b N O ~ O N O N O O~ N ~ N
~ ~ ~ ~ O ~ O ~
h i Ov 1 O~ G~ NO ONO
pN O N NO
N

O O O O O
O O

x x
3 z Q Q

~ ~ ~ ~

a . .., a u u x x x x x x O N M ~ ~h U,. z M M M M M M

~~ o~ ~ ~ N ._ '' , O

-v '~

ar ~

y O oo ON c M
O

y_.. ~
i"~ ur ~
Ar ~,_, b0 CL
~ O~ M a1 OM p c,., b_D
p. .-. .~ .-, ..-~ .....
s.. O ~

M ~ O

( M V~ M

4r O C

Cs. N .... ..... t~ 00 ..-, z cw. ~ ~ ~, ~D ~ ~O
O
~
~

~
~

z o ~ -d N ~ --~ h ~., os- ~ ~ g z o ~ M M V7 ,~ ,~

zw~~ ~ ~ ~ o O o a~ ~ ~
c~ oo .., .., ~" ~' M

~-. .~

~~ ~ o o~c ~ ~ ~ N
z x x x x x x ~ x ~

Q ~ d Q a j N ~ N N N N

c ~~ ~c a .r a~ ~ ~ ~ r- r, ~ r. c~. ~ ~ ~ r-U'~N ~ ~~~' ~~' a'~' a'~c' ~Q'~' ~,~'~.o~

U O ~ ~~o~n ~ ~ ~ ~ oo~ ~
~~oo~n ~.DO~n yco~n yoom z "L~ 7 ~ ~ ~ O ~ ~
~ 1 ~ O ~ ~' O ~
O O

Q ~ ~t ~ N N N ~ N N
N N O O O
O O

O O O O O O O O

Q

c U U

O

V x ~ GCa CA

x x x x x x O M M

M M M
~z N ~h ~ O O M M - O

r.~ Vl d O

'b ~ ~ ' O C~ ~' ~ v w N V ~D N M
b ~ O ~ N 1 ~ N

~ G

V
O ~ ~ N N ~ N O

v w a0 A~

O ~ .-~ .-., ~. .--. .-.

M M M ~ M

_w vp G.~ N .-~ ~, ~
~ ~ N - M

~

O N N M O~ ~D
Z '-' ~
~

~ ~ N .~ O~ O
b ..." N ..-. ~t M ..., v~ U

z w G p~ ~. ~ Wit' O~

U ~j N O N ~t ~O
ct z w O ~ ~ O ~

N
O ~. a> N
i n .-~ o o~
o '~ o c 0 -V~ ~n V~ v~

N

~ x x x x ~.

d a ~ Q Q

N N ~ N N N

N

U ~N ~ ~~~a~ oo~~rno~ov,~.ovovoy~ o~a.~~ ovoy~

U '~O~ '~oo~nQ'~o~n '~o~n a'~o~n '~o~n G~ o Qoz~ ~ ~ v ~NN WNN~ ~N~u1 ~ ~ ~N \' N~ N~ ~ V O O
~ O

p O p O C7 O O O O

,~ O ~n rt ~ oMo M

o ~ x ~ z z vU x x x x x a w N
N

~N ~ C

U w ~ ' ~ O~ ~ Q\ ~D
b ~ O ~' ~~ M -~ N M
~

y ,_.. ~
O

~ per" 00 <M 00 Y> O
N M

N

V M v'~ M N
't z w ~ O ~ ~ O ~ N O~
~

O ~ N O

~"Q~Q. N Wit' V1 C

z o ~ "O ~ O Wit' N
~

~ U N tt __.

M
~o h ~ O .

c ~,.., a\ .o ~n ~r o N
a ~' O o a~
~
U ~

n H ~

~ N o0 (w D N -~

!

N t N

x ~ x ' N N N N

'~ 'c 'c ~~ U U

c. a.

h h h h h h h h h h ~ ovov'r'~ova~'~'o,ow'r'ovovov'~'ovo~~'r'o~Q.~'r'~
~'~ . ~'~ ~r,. ~~. ~t ~t~

~~ l ~~ ". ,. ~~
U ~ ap vD ~ yp O Q,~ ~~ ~
O v' yp O V7 op yp yp yp O
v~ O ~n O ~n ~n "~ C~ N 01 N ~ N 4\ N Ov Ov N
Z b O ~ O V~'1 O N O ~ N O V1o ~

O O O Q O O O p O O O O

O

00 h M M V1 V1 G1 a o o h h Q ~

~

~ x o _ x x x x x ~ o ~t ~n w o h h ue ~ Q N

d V
-U ',-. ~ d~ --~ Q\ N --, v M M ~ N M
O
O

~

w b4 Cl.
O oo N O o0 M

~ ~ O V'1 ~ ~ Or M 00 ~ ...r Ov Ov O Gl M .--n e C
z ~ ~ b M 00 O M -~ .-U

O~ I~ M o0 t~
~

t~ ~ o ~n o C/~ ~-~ --~ ~~ N N

M

Q1 ~D M 00 O z O ~ C' E-.. .--~ N
C/~

~

N V1 N ~O

y Q Q a ;x a a N N N ~~ N N

' ' U ~~~~ ~~ r ~o~~~ ~o~~o yo~~a~ ~oyo~
~N a ~

U yco~n ~~o~n ~~ov~ yoo~n ~~om ~
~ o z ~ ~ ~ ~' V

a ~ Ov N Ov N ~ N O~ N Ov N Ov N
~ ~ ~ ~ ~ v ~ ~ ~

O O p O p O p O p O p O

M M

U a a z~ a ~ ~ pq U U

U

x x x x x ~ n u v ~ ~ , ~z ~~ orx ~ -".~ M N ~' M M

O

'-' O ~ ~'~ M ~ N M N M

y O
H

c,~, 04 C3, O~~ O ~ ~ O N O

b 0 ~, _ ~ rr .~-w ~ ~.r rj M t M M V7 M

M O ~ N M M

C, .-. V1 O~ N ~t N

C
b M N M

Ov N ~t N

M ~ N

Cn ~~ N M

z ,~" C p~ ~ Ov M I~ N

O ~ N 00 N N
v -' U w ~

E"' O' ~h N ~ ~ 0~0 '~t E- z v~ N M

~

~

a Q a Q a j N N ~ N N N

v v a v v N

UyN

U G~ ~~ov- y~ ~n ~~ ~n ~~o~n ~~ao~ ~~n ~O ov-, [~ I~-yOy ~NOv I~NOW ',-NOv ~NQI I,..yOy 'C ~ O~ O~ O~ CT O O~
<C ~ z ~ O N O N O N O N N O O N
O O O O O

W W U

c Q

0. ~ x ~ ~ 4 x x x x x x C O N N M ~t c~

, O ~. _ O ~ N N

'b :p ~ O L N ~ N ON M
~~

py_.. ~
O
C1, ~ ~

00 O O~ O

~ 4.

~'~~ ~ ~ M

z _w ~n O ~ N~ ~ ~ ~D ~ N ~ N

V N N N Q~ N

N

O ~O M N
z ~

O ~ ~ N N Q\ N
U

H ~O pp ~D ~ ~O '~ 00 z o o ~ ~ ~ ~ ~ ~ o s M

f'-. p" ~-~ M ~
4-~
z O ~ ~ ~ ~'_' ~, N M

in E'" Q' M M d' N ~ 'n O
~
z~

, z ~ ~ z N ~ N vp N vp ~D
,'X~, x x x x x ~

N N N N ~~' w N

N

ar ~ ~ ~ ~ ~ ~ ~ ~ ~ [n ~ [(~ ~ [n U ' ~ N ~ cy ow ~ ov oy ~ ~ ~ av oy i ov ov o~ ~., oy. ay ~. o, o~ av o, ~' '~ ' ' ' o~n U W o~ 'v o ~ ~o~n o~n ~o~n ooo n ~ o .o n Q ~ z ~ ~ N ~ j ~ N O ~ j Ov j Q\ N
O ~ O N O ~ ~ O n O n O ~n N N N N N N N O

p O O O O O O
O O O O O

M V~ ~ M ~ ~D O~

C7 x z w ~ ~ Q Q ~ W w 3 o _ x x x x x ~ x o ~n ~ ~o ~ t~ oo a\

O ~

f ~n ~O ~D d' M

a' U N N M ~ M N
~ ~'.~

~.
~ f ~" CJ7 ,_, O I~' O N

M M ~! M 41 z c,.., M O Ov Ov y~
~
~
G ~"

, ~ ~ N ~ M
"
~
~ G., Lt .i c z~. ~b M

o ~
v~ rr~ N .-. M

U

M OpO

N M ~' t'~ V1 ~n U ~

00 ~n .- c~ ~ o z~~~ N O ~ N ~ N

~

N ,~C, x ~C x N

G, Q, G, 0.
Q Q Q Q

N N N N

N ~ ~ j c~- ~ r- ~ ~ c, U'~N i ~~~~ ~ov.'~~.o,ooo~~o y~~ov goyov c~~~ov U 0~1 NO~n ~~o~n ~~oo~n woo~n yoo~ yoo~n ~ O~ j O~ j ~ N ~ j CT j ~ j ~ v1'~ ~ i ~ in ~ ~ ~ i y!
i O O O O O O p O O O O O

~ ~

_ 3 ~ ~ ~

x w w Q Q

x x x x x c~

M
' N O ~ N M

O O ct ~

b N O H M M N N M
~

f.., ~ O
H

O O O N N O

C/~ p., .-.

z M V'I V7 M M

w 2 w v O c~ r' O ~ N M
G ~, ~..

Q ~O o M .-O O (~ ~
~ N

LL N
'' v7 C/~

z ~
~b o ~ N l~ N

N ~ N M

O O 000 ~ ~ N
%

C
ih zw ~ o" ~ ~ O

n ;,.~
V c p F" ~ M 0 ~ ~ ~ N
z 04 O~ ~' E"~ ~ N ~., ~

x x x x x ~.

Q Q ~ ~ a a N N N N N N

.r a~ t~ ~ t~ ~ r- ~ t~ ~ t~
U'~N ~ ov.~' o go'~' o'~' g'~' c~o~~av a'~' o p yao~ p ~~o~n o o,~o~n o~~o yoo~ ycoln n ~zb ~ ~ jO~ n ~NO~ ~NOin ~ jO
O~ ~NO i a n N ~ n NO NO
N NO NO
N

O O O O O O
p O

a~ ~ ~ W a ~

~

O O
x x x x x x ~z N N

'b O ~

'~ L~ ~ j L1.

w b_U O.
M O O N

p"

~_~~~

O C

Q' ~D d' ~U "" t'~ N
z w w ~ N t~ N N N N

C
O ~ ..... ~ N

p N f N N N N
' ~

~ U

o _ _ _ O O C% ~ N t~- ~ N
M

N ~ __ ~' .~ M M

N ~

O

y ~ ~ N
O

Zi~~~C N ~ ~ N 000 x O 0.. fl. U U O-~ Gh N N N

~ ~ N

a ~ Q a' a~
U'~N ~s g'o~ g~o g con o~~~ g~~~ g~~.~
i E~ ~ ~ ~ ~ ~N ~N ~N
~N ~

zb O vOv vO~ O O~ O~
~ON ~ON ~ONO ~pNO ~pN ~pNO

O O O

Ov Ov Q\
~

d ~ a. ~ ~ U

~ W

E ~ ~C p -~

x x x x x x ~z 00 -~ !w 0 O O M ~ .-. ~ 00 ~

r. I
.l b d '~ c ... O _ ~~j 4 O ~ ('NV _ _ ~ N M
~ M M

y _~.. y O
N

~ ~

w ~
O N O O Ov N O

V7 G.

.-., ~ L1~

w E-' O c'~ ~-~ O\ O d.
O

N 00 vp O O~ O
o 0 0 U

z o ~ ~ ; M o o o z w ~ cT' ~ o ~"' ~t Ov v~
~
U ~

n O ~ N

~ ~ pp O N M 00 ~O O~

N ~"

~

x 00 00 00 N O 00 O

a x N

N N N N N

a a U'~N ~s o~~.o' g~~ov oov.d.o~oa~~y ooyov ooyo~

U o ~ ovoo~n ~o~n voov~ o.nov, ~~o~n ~~o~n ~' ~zb p N p N p N p N O N O N
O O O O O O

~

d x ' ~ a t7 A w a w ~ x x x x x x -i N M M
c~

O O N M

O

~ M ~ V~'1 '~' M

w ~
~ M ~--~ V7 ~ M

~~~~r~'~ ~ ~ ~ M

~1 E"' O c~ ~
'i' ~ ~.. N ~ O
p w ~ ~ ~

z ~ ~ o ~b o M

W,., c v~ ~r ~t oo ~ 0 0 ~ 00 N

O O ~ M O~ .~ 0 ' ~

~n U ~' M

E-~ o" M

O
E.., z V1 t~ 00 .-~ N .-za~
x O N N ~ ~ N N

N

~ N N N N N

y U ~N ~a $o, c~o~ oo~.~.o~ooya~ go,~.o~oo~.~a.
U a, a~ o~n o oo~ om ~ o~~n wc'~~n o y ~ ~~ y ~ yo O yo QLWZ ~ ~ ANON ~NO~ ~NO~ ~NO~ ~NO~
~N O O O
O

O O O O O O O O

M
M M ~ ~ N
' N V
J

~ x x x x ~

z c~

O a\ ~ a\ ~ p ' rY v0 M C M
~

O _ _ O M ~ fV M M M

V
O
~
Gr ~ ~

4., b4 O
O V ~ ~~d' N O M O

7 G, ~-.a w M

M M M

z~.~o~~ ~ ~ o w Q ~ G, vo ~n N ~ M

z ~ ~ M ~ o ;

U ~o ~n ~n ~ M

zw~~ ~ ~ ~ ~; N

M ~ 00 V~ M M N M

,~

00 ~' N

O
z O ~O O~

~.
~

z~~ ~ ~ N
x o x ~. ~. x .

o ~ ~ Q

Q Q ~

N ~ ~ N N N

A o . ~ ~ a U'~N ~s o~~' gQ'd-o'oQ'd.' ga'~' oa'~' oo,~o~

U O ~ ~ov~ ~o~n ~o~n ~o~n tom ~o~n ~ Ov N ~ N O~ N Ov N O~ N ~ N
~ ~ ~ ~ N ~ ~ ~ ~ ~ V~'1 ~ ~
O O

c O O p O O O O O p O

~O l~ N V7 z~ ~' w w ~

z a w ~

U

x x x x x c~

N ~ v'7M

G

V ~.. N v M N M
~ O ~ ~ M N M N M N

O ~ ~ O

c,., by a. ~, ~ M N M ON OM N

~. -~ -, . .

~

M M M M

O

N

N

C
,," O o0 I~ w D ~t vo cT ~ O O~ N N

O Cn N 00 ,_, ~ I
M V1 f~ O M

O 0 ~ N l~- i~ ,_, 00 C/~ ~

,-, ~. N

~

,, ~ N N o_O
0' ~ .~
O

O N ~ I' Ct N
~
U ~

n 00 ~ O N O c~r1 O M 00 I~ ~ V'7 00 ~f 1 E-. V7 .-, .-, ~.. N .~ N

za~
x O N ~ ~ ~ N ~ N

N

N N N N ~~ N N

' a a a~ ~ ~ ~ ~ _~ ~ ~ _~ ~ _~ ~ _~
~ l N

U ~o~ Wo~ OvpO ~c 0 D~~ Ov'00 O~o ~ i n v n n ~

z ~ ~ ! i ~ N ~' 1 ~ ~ ~ N i ~ ~

~ N ~ n ~ ~ ~ ~ ~ v N N ~
d ~ N ~ ~ ~ ~
O

O O O O O O O O O O O O O

C~ ~ M ~- N

d ~ ~C

~ ~ w N n a ~ a o _ x x x x x UU

x x O O N M ~t v~ ~ ~O ~D

c~

M
~ ~ ~h ON

O ~ l~ I h 'b :r O
p V .~; N N M ~ N

N C

a ~ w ~ ~ M N o0 O ~ N M

~

ii, v' ~

m z ~ ~ N
~
~~

o ~
~

z w cd ~ M

..-. o O O V' M
U r.

~r a~ ~ oo t~
M ~

oc, ~ o a~ ~. O
V7 ~ o M (/7 .-, .-. N

z~,~o~

p O y ~ N ~ 00 U~

O O ~. M 00 z ~ ~ ~~ N

E-. .-. ~
C~

O
O

k ~ ~ ~ ~ k Q Q ~ d Q

N N N N N N

N = ,' ""o'~' ""a'~ '-"'a'~o'""'a'~'""'Q,~ov U' "'~,~ ' ~ ~ ~no~n ~ o~o~n ~o n ~~o~n U o ~ ~o n o.flo~n Q ~ ~ ~ ~ N ~ N ~ N ~
Z ~ ~ ~ N ~ N ~ ~ ~ ~
~

~ N ~ ~ ~ O O O O O
O

O O O O O

M M

d d ~ Ca ~ ~ Q Q x x x x x x o r- o0 0o a. o. o O ~

o0 ~ ~ N N

O_ .

_ _ b ~ a" N M M ~ M
~

i_.. ~ O
V ur 4r ~

y Qr ~' ~

w ~
a ~
(3; 01 N
.

, ,~
~

C

O N o0 \O ~ 00 z ~ M , M

Z w ~ N f~' ~ ~"

p O ~-" ~' ~ o0 ' ~H o" ~ ~ ~

z'~ox O O N N O O

a" ,'~' ~C ~C ~C ~C

U G-i G~, O.r C, Cl, N

N N N N N

y y ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
U ' ~ N ~ ~ ~ ~ ~ h .-~
-~ ov .--~ ~., .-~ -~ ov ov ov ov ov ov ov a, o~ ov o~ ' U C~ ~~~n ~oon Q,,~on ~~on ~~c ~on ~n ~NO~I ~NOt~'~1~NO~ ~NO~ ~NO~ ~NOV~1 O O O O O O O O O p O

p ~ M

Q H

A

x x x x x x ~z c~

opo ~ ~ ono N N N

O _ b O ~ ~~ ON N N ~ ~ ~t M

~ ~ 0 ~ ~ ~

O N N V1 ~t C/] (~, ~

~. .--~ .... -~ G.

z _w ' O O ~ ~ ~ N N M N

~O
Q. N ~ 00 ~ ~D ~ Wit' z ''" ~ ~ N

b ~ N N ~
N ,~ 00 00 ~n U

C pm n ~t ~ ~ oNO ~ N
M

O ~ ~ ~ O O V~ ~' M
00 d' ~

N --. N

C p ~ N ~O 00 O O ~ ~ ~-~ O O

~n U

za~ox O O O N O

N N

~1. Qr d a d Q Q W a N N N N N ~ N

N

~

~ ~~on aon ~~on ~on p~on c ~oon ~

z ~ N ~ ~ ~N ~ ~N~~
\' ~ ~ ~

~ N~~ N~ N~ N~ ~~ 0 O O
Q~ 1 O ~0 O

O O O O O O O O O

Q
H

a a V W

x x O ~ ~ a\ Q~ O~ D\ O~
~z t'~ I~ I_~~ N N

,...a N N

'b C

O

Qv ~ .-r M
w ~1' V ~ N M M ~

O

,,,,., pp ~L O OM N d' LL, ~ L~

~

~
~o~.

O

w C

O N M ~O
r-o H C Q"
00 N .-. ~ 00 ..., O ~~ ~ p ~ ~ N t M N N N

O~ h ~ o v~
o '-' in U ~' ~E"~Q' O ~ M ~ ~ V1 z ~

E.r ~-~ N N N
C/~

ZI~~~C," N O O

Q Q Q Q

' N N N N N
. .

~ C

r.~ r~ r-~ r.~

C~ ~ ~ ~ ~ n ~ ~
U'~N rd ~'~ ~'~ ~ ~ ~ C
a' a' ""~ ~"~ -'~ ~o, c' Q' ov cT

U L7 o~ i ~con ~~on a,~on oon ~~on Z 'b ~ ~ ~ ~ ~
~ ~'" j ~ ~

Q Q N N N ~ N ~ N ~ ~ j v ~
~

O O O O O O O O O O O O

~ w Q w w w as s as a a W w w a x x x x x x ' O

z WO 98/39448 PCT/~JS98104493 . ... O N
O N ~ ~ v~ M

O Ow 1 'b 4-. ~ O O~ O~ O ~ M C ~1 O N N
A

V

w M

~ ~ ~ ~ " -",~, ~ ~
~ Ar a ~
o ~

~
~
d ~.
~ a, ~ O

~ ,~ N -~ N N t ~ , r -y d M
_D
CL
LT

r C~

Z ~ N M O
~ b U

M ~ ~ cn N

in U ~ 'O N ~

.n U ~

~ ~ M ~ ~O V7 ~

0 ~ ~ ~ M N
..

~ ~, ~ ~ ~

~

~ ~ N ~~ N

N

x ~ ~

~. ~ ~ Q

'""' N N

~ N p . . .

a. .~ ~ a c ~t~~ ~~~~ .~~~~
U ~ ~ p n N ~ ~ ~
p o o ~N 0~~ ~N 0~~~ ~ o o~ ~ o'~ ~

b ~NO~ O~ _ _ N~~ ~N~~ ~'NONO
~N~ N O~ (~
~

N N O O O O O O O
O

p O
O

N ~ O O

Z ~ W N

r~ a ~

U ~ x x x ~

x x x ~ ,-,N N M

o o ~

~ ~ ~

r M M 00 r1' M
1p O O N .-. f~ f".

.-. O _ _ O M M v0 c~~'1 N~ ~

w ~D A.
M

w N~ ~ ~ M

M M -~
L,~ ~ G, M M O~ ~ .-p ~'b M M ~ O

Zw ~ v' y 0 M O ~
O

.-. .--m -" p I~ I', p ~ p O ~O Ov M O ~U

v~'1 ~ ~ M N _ s '~t U ~

n N N ~ M
~

N ~ .- ~ ~f' M 00 -~

N ~_ M
za~ N N
~

O ~ N .--~

w. 4.

G~ 0~ Ar w w w a a a N N N

a a a r v v N N N

a~
U oN ~ ~'o, .-.a,~o'.-.o~~~-.~~ov .-.oy"o~--~~~ov o, 0\"~\ ~\~\ ~\, 0\'~'\ p\~t'\
0\'~\ \

N ~N ~N ~N O
-~ ' , ~zb Ov O Ov ~NOI Ov NO~
aG~ Ov \ Q' a, O~ ~
O~ C'~

~ ONO ONO ONO ONO ONO ONO

~ ~ ~

a U U U ~. w G
i.. z"

z ~ oa m a~ a a a a a o ~ > > >

U x x x x x x a 0 0 0 0 0 0 ~O O O ~ M

O N

G

.-. O_ U c,.., U .~ ~, y-~ Q1 ~ d' .

~b ~ O U M M N N M N
C

y_., U O
s"' ~Ir C~

''' CL
p ~ ~ ~ ~ N N ~ N

~ ~_ A~
O U .-. .-, .-~ .-.
~ Ar z ~", ~ ~ ' . ~ o cw ~ ' ~ v~ ~ , ~ M N
~ G, ~

"~

~~....,, .-~ pv o0 O

U N ~ due' N

o ~n oo ~ a. o ~ ~ 0 0 M

t~ ~ 00 00 O ~ U ~ ~ ~ ~ N N

~n U ~

N O

z~~~ ~ N N ~ ' N

x x x ~ x ~

Q

Q Q a Q a N N N N N N

U ~' ~ a'~' a'~Q' ' ~ '~tQ' N ~ ~' ~ o~ v o o o o oo ~ N ~ N ~ N ~ N ~ N ~ N
~ ~-~ p~ ~ ~'' ~ ~ ~-~ O~
~' .-, b ~ ~ ~ ~ ~ j ~ j ~ N ~ N
O ~n O n O n O ~n O tn O ~
p N p N N N N O N O

O O

~, W W

x ~ x x x x z 'o o ~o ~o o o .,. r , ~ pLx N O M p ~ N

~ ,-. .--~ .~r N ~O M
O

O

v 4... ~ .--n w ~D ~
M N M ~ N

o_p G~. ..." .-, .-.
w O ~
w ~ 0., H
v ~

G. ~ ~!1 N o0 O l~
~ (~ ~~
~

~ M M ~ M
O .-.. .-.~ N .-. M
pp p~
~
~

~n ' ' cil O V'1 Y1 N 00 I
O

O l~ ~~ M M M
N ..-~ N M

z ~, ~ ~. ~, M ~ ~ ~.

o g o ~

z o o ~n U

O M 00 ~

N ~ l~
O N l~ ~O V7 ~, a ~. ~ ~ o ~ o z~~x x x x x x x x x x x ~ x p N N N N N N

. . .

~ ~ ~

"a' U o.,. yoo~n o~'r~" o"~~~ o o..",~1 ~O ~'l E" t~~OW ~-vOW ~vOW ~NOW ~NOv tINO.-.~
"L7 Ov Ov CT Ov cT O~
~
z ~ ONO ONO QNO ONO ONO ONO
~

A o 0 0 Q

Q O

x x x x x x ~ o o ~ '~ ~' z o a\ 00 O O N N ~-~ O~

p U Q c,., N .--~ p~ ~O M
~ . p '-d ~ O ~ N M ~ --~ N
~

w ~ N O ~ ~ N

_~

u.

M ~ y n o ~ ~ ~ ip t~
p .~ bpi ~t p z b o ~ ~ ~

rn U .~ oo ~, N

zw~~ ~ ~

p ~ ~ m o~ ~o ~o .....

o ~ ~ ooo ~ c w sn U

'~ E-~ Q" ~ o M ~ O

~
z~

, , z~~~~

x x x x x x Q a Q Q

N N N N

'c c ~c ~ ~ ~ ~ ~ ~ ~ ~ t~ ~ r~
U'~N ~ oy' ~~' a'~' o'~' oa'~' o~~ov U o y o o o woo~n yoo~n ~~o~
oo~n ~ov woo~

Q ~ z ~ ~ j j O ~ j ~ N ~ j ~ N O
O v i O O ~ O ~ i i i N n NO ONO NO ONO
O~
N

O O O O
O O

.-~ O O ~n M M
~

z a p ~ ~ ~

~~ O E- 0 0 ~ ~

x x x x x x N M M ~t o O o. o pO 'd' M M N M N
U 4.. ~ ~ C O~ .-r .-., t'_~. p V ~ M N M ~-a-'~ ~Cl.
~~4. ao~
~00000~0 o a, w n ~ n v ~ '~ f.~. 00 Wo in N .-.
w p C~ r1' ~ ~ ~ N
in V N
....., ,r, N v, ~ O
M~~0~1~~OMO
ef in M N --r V1 00 ~ tt z p p ~, .... .-, ~ ~ ~ N
M N 'o ~E-.v'~v~~~~°
M
~z~ ~. ~ N ~ 00 ,'~ N N ~ N ~ N
p Q "~ d' 'd Q Q
j N N N N N N .
.C .~
r.. N l~ r' I~ ~' I~- ~'~' l~ ~ I~ (~ ('~ l~
~ N GT ~ Ov N Ov ~ ~ N Ov ~ Cv N ~ ~ Ov N Ov ~ ~ N U ~ CT
U ~ ° c ~ n ~ c~ n ~~o n ~~~ n °~~~ n ~~~ n apz ~ ~cV~ n~c~°N n~N° n~cy~V"~'~ ~ i~ n~N~ n O O O O O O O O O O O O
N
z~ ~ c~ ~ ~ a a x x x x x x ~ M OM

O~ ( G

-p ~ O V ~ M ~~ N N N
.~

O~~ c~ M ~ N N N

~' .., Ar v O Q, ~ N V' ad ~

~ p '~' ~ '-"' ~ N
,, w N ch O ~ ~ ~ ~ Q1 N

'~ U

~-~ rt 00 ~ N V'1 z w '~t N 00 M v0 O 0 ~ I~ N ~ O~ ~O v7 M

~ ~ ~ i p 0 p ~ N
"" p E-~ a" ~ t ~

z~ ~ ~ o ~ o N M cf M M l~ M M M

.

Q

Q Q d a fix N N N N

a, .r a~ ~~~ ~~~ ~~--~ ~ ~ c~~c~ c~~t~
U Wn N e"d N Oy. N py. N py. N Oy. N ~ N O~
Ov O~ ~ O~ ~ ~ ~.
O~

O A U o~o~n o coin o~aO~n ~~0~ ~~o~
WoO~

b ~ N ~ N ~ j ~ N ~ ~I ~ N
~ ~n ~ i ~ i ~ in ~ i ~ i O O O O O O O O O

O O O

'~ ~, ~, M ..-. M
L ~ ~O ~O ~' M N

N ~ Q

z~ c m aa u o 7 a ~ ~ ~ N

U ~ U" Q Ar x x x x x O N N N
N N N N
..-. ~. ~.

r ~.

~ ' vi7 ~ ~ M

'~7 :j O
~

_ _ b ~i' M M ~ N
O V .~

~_ ~ O
~"' ur ~
~

O O c0 z~ ~b N

O y .-, O o0 N ,~ 00 O .-. ..~ t' W 1 C/7 .-, .-.
'~ U

zw~~ '' o O ~ ~ .-. 01 d' C'~ M

C/~ N .~ ..~ N

z o o o 'r' ~n U v~ ,~ -"

o~ ~

O N ~ N Ov ~

x M M M ~ M
-. N .-r -.. .

o ~ a. N N ~ G.

d -~ x -d x d ' c ~ ~ ' c a a~ ~ ~ t~ ~ r~ ~ c~ c~ ~ c~ t1 U'~N i o~ o~ o~ o~~' ' o, ~ ~' ,~ Q' ~ oa' o~
~ .~' ~ ~ ~
~
~

H Q,O ~ GTN C~N -~ O~N O~N
Z G~N ~ ~ G~N~. ~ ~
~ ., ~ O ~ O ~ ~
~ 1 ~ ~ ~ O ~
O ~
~' O

~ O N N O N (~ N
d A 'v (~ ~ O O O
j O
v '1 O

O O O O O O O

M ~h d' O~ ~D

a~ ~ x x x x >

~ x ~ w ~ ~

x x x x x x z N N N N N N

O y ~ Q ' D M 00 ~i .

'b a O V N M M N
~

N t_-~ ~
O

,a._, d4 Cs. N ~ M N
O ~ ~

~ ,'''~'J. .-~ .-, ~ ~' ~~~o~.

z _ ~"' i- '~ i '~' o ~ ~ ~ (3r \D ~ ~ ~ M

C

z o ~b 'O M
Y

O~ ~, N
w o ' O "'_' ~' N (~ ~ 00 j ~

v-, U

~

~ d' N t~ ~ 41 (%

'~t ~f' d' x x x x ~ x O a~ r~ Q. a.

_ Q
N N N ~

' N ~ N

~

C C C C C

N t~ I~ I~ !'~ I~ I~ ~ I~ [~ C'~ [~ (~
U'~nN ~ Np~~~ NOV~O~ NOv~C~ Np~~~ NOv~Ov NOv~~

U Ll ~~o ~~oo ~o~ ~~o ~~o ~~o n n n n n ~ N N i N ~ N
N i ~ N N

j ~ O~ ~ ~ 01 O~ N ~
~ N N O
~ O
~

C O O O O O p O O C

~

d ~ Q j ~ U

d Gl o m ~1 ~ C7 ~U
x x x ~ x G
O -~ N N M ~t M M M M M M

o~o o ~- o ff ..."

,_, M N

~ O

_ _ _ _ ~ L~ M N M N M N

~ 0.
ur a ~ 4~
O~ ~ N ~ N OM N

~

' b4 ~

._.
O ~ ~

vp ~D

"b ~ ~ N

~ v0 ~n .-~ M ....

z~.=~ N ~ N ~ o O ~ N ~ N N

M

z ~

~

~n U

~ E-' o- '_'~ -- ~ oo vo t~

z v o cue. ~ ~ ~ M
~

i za~ox ~ N ~ N dI~' z ~, ~, ~ x . .

U U U U

N N
U
U

~

GG ~ a7 C~G1 C C

Q. Cw LL Q.

...~ U f~~ L.- I~.
l'"~ f~ h N Qv N ~ N ~
N Q1 N O~ N O~ ~ O~ ~ O~ ~ ~
~ O~ ~ Ov ~ O~

~~o ~~o~ ~o n ~ ~o ~o n ~ oo n n n ~ z ~ O ~ O N O O N O O ~
i Q O~ N tn y ~n ~ Q1 N
N O~ N Ov ~ N 01 N
N N N N

O O O O O O
O O O O O O

O O ~ ~ ~ 'n ~

z > > z z ' "

U
x x x ~ x x W n v~

M M M M M M

..-_ ~ N ~ O~

CJ ("~ '~t V~ M M

~ O_ a ' _ 'Z7 ~ M --~ N M c'~
O s""
~

~.L

'+. ~ ~'' 00 M N --~ O N
O (% M --~ N M M

~ ~

O C!) ~

~t ~' N d' O ~

Gr t~ N N ~' ~ N

C
z ,~, ~ O ~ -. ~ ~ ~r O ~ U I~~ N ~t ~' N

z ~, ~ ~- ~ ~ ~ ~

O ~ ~ O oo y n vo M N

~ ~ ~ O

~ N ~ .~ v~ N
U v' t~

n F~ a' O z ~ O oo y n ~n E-a C/~ ~

N .-., -- N

za~ v ~ N o O~C

z N

Q, T1.

Q
N

N N N

'c ~c ~c U'~N s o~~~ o~~~ o~~a' o~~' oo'~' o~~~

U G Woo~n ~o~n .noon ~o~n ~o~n ~o~n 1 n i ~ ~ N
n Ov N Q\ N O~ N Ov N av 01 ~ ~ ~ ~ ~ N ~
~

O O O O O O O O p O p O

N O O ~ O O

UU

x x x x x x 00 0~ ~ o M M M ~1' Wit' d' _.

,_",, N

'~

M I N
N N N N

N

~

4. 04 G.
~ ~ ~1 N N N NO

..-., .--~ ~.

~a~'' H
o w w z~~

v~ V ~ ~ ~ ~' r o~"o M ~ N M

O C~
O

z 4. c a. o ~ o~

V~ ~ ~ cw E-' ~' ~ ~ 00 O M M

Hz~ ~ ~ ~ o x ~ ~ x . , . .

0 0 ~ ~ ~., ~ ~ ..~

j .
~ A

. .

' U
~ N ~

U ~ ycov~ yoo~n ~~o~n ~~o~n ~~o~n ~~o~n Q ~ z b ~ N Ov N O~ ~ Ov N ~U N
~ V~"'t~ ~ ~ ~ ~ ~ ~ ~

O O O O O O O O

p p O O

t~ I~

z~ ~ ~ ~ ~

n x H ~ ~ w w x ~ x x x x N M M ~ v~ 4n '-' ,n ~ N
V7 ~ ~ M V7 O M

~a _ ~ O_ _ a O V .~ N M N M N N

s_.. ~ O
G

~
.

~~w O ~ ~ N M N ~ N N

O ~ ~

' .

~
~
~

E" N N
n O c~ a c ~ ~ N M
, O

~ ~ ~ ~ N N

~

C
O

M

N N N ~,' O ~ ~ 00 ~_ N oNo U o0 ~ ~

N
M

" ~ ~

O ~ O
"_' ' V ~' w V~

H Q' 00 O~ ~ 00 0~ 00 ~

N N

za~ N
~

O' N N N

>C >C x ~. N

o A, G, .~ .~ Q
~ ~

U Q Q O O Q a~ 'O ~

N N ~ ~ N

s3., n. y p"

U'~nN c~ ~~~r' ~a'~t'MpQ'~t'~a'~t' M' oQ'rt, o\' ~

U ~ L1 ~~o~ ~~o~n ~~om ~~o~n ~r, yoo~ ~~c ~

O z ~ ~ N ~ N N O N O O j O Ov N
O ~ O ~ ~ i O ~ O v~
O

Q N v7 1 O~ NO v NO
~ N D\ NO NO
N

c O O 0 O O O
O O p O O

~

o z z w w x a ~

_ x x x x z x x c~
~r r N o0 M cf' ~ C

N
U '~ , ~
~

+, ~" ,_, (~ .-r . M M ~~ M
b ~ O ~' LJ

W _-. ~
O
A
~

"' ~L V1 w O O O ~O O

~ ~

4 ~.
G

_ ""' "' O ~
Ar E"'' v O v N o0 a3 G O

, _ ' ' ct ~ O N N vp C

w w C Q' ~ O h- MO
Z

0 o a, O
~ ~ O

V7 N .-, N

M (~

N
~ ~ N

v~, U 'r~ --~

Q_\

~-' N Ov N
C/~

vp N ~L7 N v0 x x x x x x x x x Q Q a Q d ' N N N N N

v ~. ~ W~- ~ r- c, ~ ~ r. ~
U~ ~ Mp MQ Mp MQ M~~Q~
~ M~~O ~~O ~ ~~O T
~ 1~0 ~ 1~C

~nN _ _ _ _ _ 1 ~
_ _ _ _ \

~ ~ L ~ ~ yD O ~ ~D yD O yD O ~
V7 ~n O ~n ~ vo z .b O ~ O N 1' O O ~ O ~
O ~

'~ L ~ N CT N V Q, N O~ N Ov N
O p t ~ p p Q, N 1 p p O O O O O O

z~ v w w n x a o _ x ~ x ~U

x x x --~ --~ N N M

c~

ocL ~ ~ ~ o ~,] O M M N

~ _O _ b a O ~-' lp ~' M ~' M
t'.

c~ L_ y O

Or ~ ~ ~

O ~ ~ ~ M

O ~ ~

O
~ N ~

Ov ~t 0 G. N M N V'~ M 0 N

z orb N M N N

O 00 ~ 00 ~-W D
z 4-. ~ Q' ~ f~- M N

M
N N N

C ~' ~ Q' ~D M O
~ M

0 O l~ I~ 00 00 ~
N N W t' M

V1 O M ~ M ~_O

M N

N

x ~ x x x x x x x x x x d Q Q d Q d N N N N N N

' a' U'~N ~ oa~~' oo'~' v' oQ'~Q' oa'v o~~av oo' ' yoo~ ~~o~n yoo~n yoom ~~o~n yoo~n O ~ O ~ ~' ' N O N O
N O N O ~

pv N O~ N V V O~ O~
N N 1 Q~ NO ~
Ov ~ NO
N NO

O O O O O O
O O O

00 ~ ~ ~

~ 0 N r-~ '.~ ~ LZ, x x x x x x x x ' ~ ~t v, Tw o t~

r r O N M

N ~ N

~ O_ .

b a s" ~ N '~t N
~

N V~' N

~_ p N ~ M

w~ _ z~.~ o ~ . ~ N
_~ O

_ M N ~7 ~ f1.
LL

, G _ O 0 ~ p ~ N

opU ~, N o ,n f-~ ~.,... w o o' .~ o c a~ 0 0 z o~ ~ ~

M N

G ~ 00 00 \o o v ~ v E"" ~ O~ ~ N 00 O

t,-x .~ x x k a x ~C

O ~ U U
v..

Q Q Q" ~r j N ~ ~ N N urn a~ o Q

. ~ ~ .

a~ r~ 4., c~ o~ ~. a~ ~ o~ ~ c~ r- a~
U ~ v~ N ~ c, c~ ~ c~ ~
~ M O~ M (T M (7~ M ~ tr1 M p~
01 ~ O~ a1 ~ ~ O'~

Uo ~ ~~on ~~,~n ~~on ~oon ~~on ~c>on Q O~ N Q1 N Ov N Ov N Qv N O~ N
' z O ~ O ~ O ~ O ~ O ~ O ~

L O O N O O O O O N O O
~

O O O

A N N N N N

Q

c ~

~ ~ 2 U
o ~ U d x x x x x v c~ oo ~ O O

. .

N
N o0 ~ .~ N
U Q c j . ...., . N
i., M M
~

~

'J c,._, D~ Q. O O
~ ~

Q

~'~~.

z w ~ ~n M N ~ .~ o c a ~ ~ ~ ~~ ~ ~ M
~ Gr LZ

r Z ''-" ~ ~ M N ~ '~ O
b ~ U ~ '~t Ov ~ M

H a~ ' -. 00 O M O N

0~~ ~ ~ ~ N oNo cn z c~-. C l~ M N ~ N
p' 00 00 ~ ~ N ,n o ~ o ,_, N
'~ o0 --~ .-, N .-. .-., M
rl7 za~~x ~ N ~ N ~ N

p. O. D., C1.

U U U U

~ ~ ~

~v~ ~cn ~v~ av~ N N

o o o Wi . . . n.

V N I~ ~ I~ I~ ~ h I~ ~ t~ ~ f~
"' M ~ M ~ M p1 M O~ M O~ M ~
~ O~ ~ CT ~ O~ ~ O~ ~ G~ ~ O~
~ ~

on ~~p ~~on ~ oon ~~'pon ~~on ~~ o~n Z ~ h ~ N N ~
~ ~ ~ N

~ N ~ Ov N Ov N ~ ~ 0 V
Q ~ V ~ ~ Ov ~ O~
o O O 1 O

O O O O O O O O O

a a a w Q Q

UU
x x x ~ x N N M M ~i' ~ r w ~ ~ N N ~ t~

O O ~ N U1 ~D N N

Q

U d w N V'7 Ov \p M N N
.O N ~ N N N N
O

~ ~

w b,0 d.
O ~ ~ N N N N N

~ LL~

~t' v~~ 'd. ~t.

w z ~
~' o ~

E" M

O M .-.

U

v" O M ~ ~ U V1 N N ~ V1 M

w C p d~ o~o Q\
-, .-.. ....

O O ~ ~ M ~ .

in U

~N

~
~
z , ~, z,~ox ~ N

x x x x ~.
.

Q Q a ~x Q

N N N ,~v~ N N

'c 'c a a U in N ~ M ~ M Q~1 M ~ M ~ M Q1 C'~
~ ~ ~ O~ ~ ' ~ O~ ~ O~ O~
~ ~

O ~ ~ N O~ N ~ N ~ N ~ N ~ N
U p ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~

, . ~ ! ~N~ ~N~~ ~Ny1 ~ ~ ~N V
~

~ N~ vN~ ~~ 1 O O O
O O O

c p O p O O O p m_ n vn M M

x O N N

w Q
~

A O ~ x N

0. G.
x x x x WO 98139448 PCT/US98l04493 N

~D M ct U Q c,.., -~ L O V M N N M N OM
O

cue, by L1~ ~ N N ~ N N
O rj~ ~

~'i'.. ~ ....
O G4C3r Cn z~,~O~tl. N N V1 ~ O

V1 O LL O\ ~ ~ ~ O -, Q
Cl V~

C
4.. O N N

'r, o, ~ ate.

U

Q\

N M ~ N

~" O" Ov O ~D

tn M ~ O~ O~

z~~ox ~ ~ ~ o N r.. --~ M

G3. Q, L~..

Q a Q

N N ~ N N N

U.oN i ~O~Ov pOvO~~ p~0~0~ pOvO~Ovp~O,~s pO~O,~s ~

U p O ~~oo~n ~~oo~n ~~o~n ~~oo~n ~~o~n ~~o~n <C 0 z O Ov N ~ N O~ N O~ N Ov ~
O~ O ~ O N O i O ~ O ~
j ~ O O O O O O p O

O O O O

Oy Y d' ~r v Q ~ ~

~ ~ ~ ~

v x x x x x x ~4.,~ ~ ~ cT r ~ fJ N

U _.
O
'~

U _ c._, N N ~ M ~ M
q~
.
b v O
i' ~

U
i_..
~
O
'~
LL
(/~
L1..

~_ O V O N ~ O O~ O

l (Z, J

~W
O
~
~

'"

r G1, r M M ~ ~ N
~!7 N

r r~ ~ M M ~ N
U N

z~~~ o ~ ~ ~ _.
H

O ~ In M N ~ .-.
~ "
U

M ~ ~r N N .-~ .-.

__ .

r r ~
~' n U

off o ~ ~ o ~

E-' ~ N N
z ~

N N

z'~o~ ~ ~ o ~ o M -~ M

~' C1' '~ ~v y0 Ar U ~ U ~ G, C, Qr N ~ x N N N

~ ~r n U'~N ~~p~ d~~~~ ~t~~~ ~~~ ~ror\,~~~~~
~

U yoo~n yoo~n ~~ov, yoo~ voo~n o o ~
L1 ~N
.~
E_"
C

U rvOv rvOv rvOv rNO~ r'O\ O
~'O ~ O ~ p ~ p ~ O ~ p ~ p N O N O N N O N O N O

O

N N

z Q ~ m as as ~

w w x x x x x z M ~t ~ V'1 r r r r r r o ~n M M M N N N

.-~ O

_ _ Lj a O V N trt ct M ~' , i~

~ O
N
Ar ~ ~

~_~' N O M O oO

~

G4 ~.
G ~ ~

da~
~"

z z~-~ ~ ~ ~ ~ o =~

~ ~P ~-~ l~ ~ ~ rt' LL

z ~

o v z ~. ~ ~- ~ ~ ~ ' O 0 ~ t/W 1 ~ N

z a ~

o ~t ~. c~ a, N

U ~

E"'~ ~ 00 O M ~ O~

~z~

0 0~0 0 0 0 0~0 ~ x x x x Q Q Q Q Q d N N N N N N

~o~ ~o~ ~o~ ~o~'' ~o~ ~o~
U'~N ~ o~~n' ~~n' oa'm' ~a',n' o~inv' o~v~o~

(~ ~p o ~ o ~ o ~p o ~ ~p v> ~p o W p ~n ~n o n ~ o ~n z b ~ ~ N N ~ Ov N O~ N
O v ~ ~ ~ ~1 Q ~ O~ N O~ N ~ 7 O O O
~ ~ O~ Ov O O

p O p O O O O

~ ~ v Q

z m Q a ~ w Q Q

x u x x x x .~
x T

cat ~ p ~ v7 ~ ~ M ~ O~

N N M -'~

w c~ .... ..-.~
V M M M M M
~d V O V
~

_i.. v O
''W ~G~

"~ w bD ~L
0 O ~ M M

t .--~ .-r .~.. ~

_ . .-, O C/~ Gr LT.

o LL N M d O
~ M ~ o z ~
~

o M N M
b C~

U

O ~ ~ - N

O ,~

M

o' o z o ~ N ~" N M
~

h ~ O ~ M
n ~z~ o ,~ ~ o o N N

a ~ o 0 x x ~. .~ .. x x ~ ~. ~ x O Clr G.i U ~ U ~ U ~ G.

' ~ ~ ~

N N ~ ~ ~ N

j ' ,''o~ r.oc~ ,r~or" nor""' ~o~ r..
U'N ~ oyna' oo~v.,ayv~,~,oyo,",o~oo~,~o~oQ.".,ov U o D ~~o~n yoov~ ~~oov, ~ c ~ oaf ~~o~n o~n ~ N O~ N O~ N ~ N ~ N ~ N
~ ~ ~ ~ N tr ~ ~ ~ ~ Q V1 O O O O O O O

O O O O O

Q O O

0 p W W ~.t, G.t, ti.

U x x x x O O ~~ ~ ~ N

WO 98/39448 ~ PCT/US98/04493 OO ~ ~ ~ N

~ N

Q
Q
O

~+. a ~ ~ O~ N ~-~ O~
~p ~ O V M ~~ M
~

N L ~ ~O
L

O oo O o0 4r ~_ 4..n rr ...w ~

O

N ~ M_ ~D V' ~O '~t ~G

~ O

~ ~ ~ d' N
O

LL N
in C%~

z b o ~ ~ c= ~ ~ o Q\ ~Y N .-.

Z ~+. ~ 0~0 N ~ N
O"

O ~ ~ N O O O

M

F-' C Q" O O d. ~D N

O U ~ ~ ~ O Ov O ~

~ M O O O O

N N M M

a o ate.
M

Q Q Q d Q Q

N N N N N N
. .

~ c U'~N c"d o~~n' oyn' ~~~n' oo'mQ' oa'm' oyno~

A ~ N ~ O~ N Ov CT N O~ N O~ N
U G ~ ~ ~ N ~ ~ ~ ~ ~ ~
~
~

. O ~ N ~ N ~ Ov N Q~ N
z N N ~ ~ ~ ~ ~

~ Ov N N ~ O~ O O
Q; ~ ~ O~ ~ O
O

O O O O O O O O

,n ~ N N O O

~1 ~ ~ G~, C~., CG1 ~Cl O

_ x x x x x M M ~ cf ~z s~
o o ~ o ...
O

~ a U Q c,.., ~., ~ .

U
M N

~ u.

w ~ OM N

~y O G_A ~. .-, G. N O~

G
z 'a-' ~
b N N
U N CT

~," c a- ov o\
z o o ci~ o00 M

H

' i U

n N N

ox M

N

N

U'~N ~ 'a'~"~,~~ro~~,,~.,~

U L1 ~ oo~ oo~n .

Q ~
z b L~ ~ NO NO

O O

~t d' ~ Q Q
O

_ x x UU

z s DEMANDES OU BREVETS VOLUMtNEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS Di'UN TOME.
CECI EST LE TOME ~ DE
NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLlCATIONS/PATENTS
THiS SECTION OF T1~IE APPLICAT10N/PATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME _~_ OF
NOTE: Far additional vo~iumes-pl~ase.cantact the Canadian Patent Office .

Claims (23)

  1. What Is Claimed Is:
    An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
    (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ
    ID
    NO:X;
    (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
    (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
    (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
    (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA
    sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
    (f) a polynucleotide which is a variant of SEQ ID NO:X;
    (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
    (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
    (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
  2. 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
  3. 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
  4. 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID
    NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ
    ID
    NO:X.
  5. . The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
  6. 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
  7. 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
  8. 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
  9. 9. A recombinant host cell produced by the method of claim 8.
  10. 10. The recombinant host cell of claim 9 comprising vector sequences.
  11. 11. An isolated polypeptide comprising an amino acid sequence at least 95%
    identical to a sequence selected from the group consisting of:
    (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
    (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
    (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
    (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
    (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
    (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

    (g) a variant of SEQ ID NO:Y;
    (h) an allelic variant of SEQ ID NO:Y; or (i) a species homologue of the SEQ ID NO:Y.
  12. 12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
  13. 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
  14. 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
  15. 15. A method of making an isolated polypeptide comprising:
    (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.
  16. 16. The polypeptide produced by claim 15.
  17. 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.
  18. 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
    (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
  19. 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
    (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
  20. 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
    (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide.
  21. 21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
  22. 22. A method of identifying an activity in a biological assay, wherein the method comprises:
    (a) expressing SEQ ID NO:X in a cell;
    (b) isolating the supernatant;
    (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity.
  23. 23. The product produced by the method of claim 22.
CA 2283299 1997-03-07 1998-03-06 186 human secreted proteins Abandoned CA2283299A1 (en)

Applications Claiming Priority (198)

Application Number Priority Date Filing Date Title
US3862197P 1997-03-07 1997-03-07
US4016197P 1997-03-07 1997-03-07
US4016297P 1997-03-07 1997-03-07
US4033697P 1997-03-07 1997-03-07
US4062697P 1997-03-07 1997-03-07
US4033497P 1997-03-07 1997-03-07
US4016397P 1997-03-07 1997-03-07
US4033397P 1997-03-07 1997-03-07
US4358097P 1997-04-11 1997-04-11
US4331297P 1997-04-11 1997-04-11
US4367497P 1997-04-11 1997-04-11
US4331397P 1997-04-11 1997-04-11
US4357897P 1997-04-11 1997-04-11
US4331197P 1997-04-11 1997-04-11
US4367097P 1997-04-11 1997-04-11
US4356897P 1997-04-11 1997-04-11
US4357697P 1997-04-11 1997-04-11
US4367197P 1997-04-11 1997-04-11
US4331497P 1997-04-11 1997-04-11
US4367297P 1997-04-11 1997-04-11
US4356997P 1997-04-11 1997-04-11
US4366997P 1997-04-11 1997-04-11
US60/040,336 1997-04-11
US60/043,314 1997-04-11
US60/043,576 1997-04-11
US60/040,163 1997-04-11
US60/043,313 1997-04-11
US60/043,670 1997-04-11
US60/043,580 1997-04-11
US60/043,311 1997-04-11
US60/040,161 1997-04-11
US60/038,621 1997-04-11
US60/043,671 1997-04-11
US60/040,333 1997-04-11
US60/043,672 1997-04-11
US60/043,674 1997-04-11
US60/040,626 1997-04-11
US60/040,334 1997-04-11
US60/043,569 1997-04-11
US60/043,312 1997-04-11
US60/043,669 1997-04-11
US60/043,578 1997-04-11
US60/043,568 1997-04-11
US60/040,162 1997-04-11
US4758497P 1997-05-23 1997-05-23
US4750097P 1997-05-23 1997-05-23
US4761597P 1997-05-23 1997-05-23
US4761497P 1997-05-23 1997-05-23
US4749297P 1997-05-23 1997-05-23
US4759497P 1997-05-23 1997-05-23
US4758197P 1997-05-23 1997-05-23
US4759997P 1997-05-23 1997-05-23
US4758697P 1997-05-23 1997-05-23
US4750197P 1997-05-23 1997-05-23
US4761297P 1997-05-23 1997-05-23
US4758397P 1997-05-23 1997-05-23
US4759697P 1997-05-23 1997-05-23
US4759397P 1997-05-23 1997-05-23
US4763397P 1997-05-23 1997-05-23
US4761397P 1997-05-23 1997-05-23
US4759797P 1997-05-23 1997-05-23
US4758597P 1997-05-23 1997-05-23
US4761797P 1997-05-23 1997-05-23
US4759297P 1997-05-23 1997-05-23
US4759097P 1997-05-23 1997-05-23
US4758297P 1997-05-23 1997-05-23
US4761897P 1997-05-23 1997-05-23
US4759597P 1997-05-23 1997-05-23
US4750397P 1997-05-23 1997-05-23
US4760097P 1997-05-23 1997-05-23
US4763297P 1997-05-23 1997-05-23
US4759897P 1997-05-23 1997-05-23
US4758797P 1997-05-23 1997-05-23
US4758997P 1997-05-23 1997-05-23
US4750297P 1997-05-23 1997-05-23
US4760197P 1997-05-23 1997-05-23
US4758897P 1997-05-23 1997-05-23
US60/047,492 1997-05-23
US60/047,589 1997-05-23
US60/047,633 1997-05-23
US60/047,587 1997-05-23
US60/047,585 1997-05-23
US60/047,632 1997-05-23
US60/047,595 1997-05-23
US60/047,586 1997-05-23
US60/047,613 1997-05-23
US60/047,584 1997-05-23
US60/047,590 1997-05-23
US60/047,581 1997-05-23
US60/047,588 1997-05-23
US60/047,617 1997-05-23
US60/047,592 1997-05-23
US60/047,599 1997-05-23
US60/047,612 1997-05-23
US60/047,615 1997-05-23
US60/047,503 1997-05-23
US60/047,594 1997-05-23
US60/047,583 1997-05-23
US60/047,614 1997-05-23
US60/047,501 1997-05-23
US60/047,618 1997-05-23
US60/047,593 1997-05-23
US60/047,598 1997-05-23
US60/047,601 1997-05-23
US60/047,582 1997-05-23
US60/047,502 1997-05-23
US60/047,596 1997-05-23
US60/047,600 1997-05-23
US60/047,597 1997-05-23
US60/047,500 1997-05-23
US4897497P 1997-06-06 1997-06-06
US4896497P 1997-06-06 1997-06-06
US60/048,974 1997-06-06
US60/048,964 1997-06-06
US4961097P 1997-06-13 1997-06-13
US60/049,610 1997-06-13
US5192697P 1997-07-08 1997-07-08
US60/051,926 1997-07-08
US5287497P 1997-07-16 1997-07-16
US60/052,874 1997-07-16
US5572497P 1997-08-18 1997-08-18
US60/055,724 1997-08-18
US5666497P 1997-08-22 1997-08-22
US5688097P 1997-08-22 1997-08-22
US5687597P 1997-08-22 1997-08-22
US5688197P 1997-08-22 1997-08-22
US5690997P 1997-08-22 1997-08-22
US5687897P 1997-08-22 1997-08-22
US5687797P 1997-08-22 1997-08-22
US5684597P 1997-08-22 1997-08-22
US5686297P 1997-08-22 1997-08-22
US5691197P 1997-08-22 1997-08-22
US5689397P 1997-08-22 1997-08-22
US5663797P 1997-08-22 1997-08-22
US5666297P 1997-08-22 1997-08-22
US5687297P 1997-08-22 1997-08-22
US5691097P 1997-08-22 1997-08-22
US5688697P 1997-08-22 1997-08-22
US5688297P 1997-08-22 1997-08-22
US5690397P 1997-08-22 1997-08-22
US5663197P 1997-08-22 1997-08-22
US5689497P 1997-08-22 1997-08-22
US5690897P 1997-08-22 1997-08-22
US5663697P 1997-08-22 1997-08-22
US5687997P 1997-08-22 1997-08-22
US5686497P 1997-08-22 1997-08-22
US5663297P 1997-08-22 1997-08-22
US5688497P 1997-08-22 1997-08-22
US5688897P 1997-08-22 1997-08-22
US5663097P 1997-08-22 1997-08-22
US5687497P 1997-08-22 1997-08-22
US5688797P 1997-08-22 1997-08-22
US5689297P 1997-08-22 1997-08-22
US5687697P 1997-08-22 1997-08-22
US5688997P 1997-08-22 1997-08-22
US60/056,876 1997-08-22
US60/056,630 1997-08-22
US60/056,881 1997-08-22
US60/056,882 1997-08-22
US60/056,875 1997-08-22
US60/056,880 1997-08-22
US60/056,908 1997-08-22
US60/056,909 1997-08-22
US60/056,911 1997-08-22
US60/056,872 1997-08-22
US60/056,864 1997-08-22
US60/056,888 1997-08-22
US60/056,879 1997-08-22
US60/056,889 1997-08-22
US60/056,874 1997-08-22
US60/056,910 1997-08-22
US60/056,632 1997-08-22
US60/056,878 1997-08-22
US60/056,886 1997-08-22
US60/056,903 1997-08-22
US60/056,884 1997-08-22
US60/056,664 1997-08-22
US60/056,662 1997-08-22
US60/056,893 1997-08-22
US60/056,636 1997-08-22
US60/056,894 1997-08-22
US60/056,637 1997-08-22
US60/056,862 1997-08-22
US60/056,887 1997-08-22
US60/056,845 1997-08-22
US60/056,877 1997-08-22
US60/056,631 1997-08-22
US60/056,892 1997-08-22
US5776197P 1997-09-05 1997-09-05
US5765097P 1997-09-05 1997-09-05
US5766997P 1997-09-05 1997-09-05
US60/057,650 1997-09-05
US60/057,761 1997-09-05
US60/057,669 1997-09-05
US5878597P 1997-09-12 1997-09-12
US60/058,785 1997-09-12
US6106097P 1997-10-02 1997-10-02
US60/061,060 1997-10-02

Publications (1)

Publication Number Publication Date
CA2283299A1 true CA2283299A1 (en) 1998-09-11

Family

ID=27587107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2283299 Abandoned CA2283299A1 (en) 1997-03-07 1998-03-06 186 human secreted proteins

Country Status (2)

Country Link
CA (1) CA2283299A1 (en)
WO (1) WO1998039448A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274312B1 (en) 1996-12-11 2001-08-14 Schering Corporation Intracellular regulatory molecules; related reagents
US6420526B1 (en) 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
US6444440B1 (en) 1997-03-07 2002-09-03 Human Genome Sciences, Inc. Vanilloid receptor-2
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2230986A1 (en) * 1997-05-07 1998-11-07 Smithkline Beecham Corporation Epo primary response gene 1, eprg1
WO1999000408A2 (en) * 1997-05-13 1999-01-07 Incyte Pharmaceuticals, Inc. Human transmembrane protein from the transmembrane 4 superfamily
US20030083461A1 (en) 1997-06-16 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
EP1627886A1 (en) 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use of them
WO1999033963A1 (en) 1997-12-31 1999-07-08 Chiron Corporation Metastatic cancer regulated gene
US7151161B1 (en) 1998-01-13 2006-12-19 Oscient Pharmaceuticals Corporation Human genes of chromosome 11q13.3
US7045333B1 (en) 1998-01-16 2006-05-16 Incyte Corporation Human protease molecules
EP1066381A1 (en) * 1998-01-27 2001-01-10 Smithkline Beecham Plc Human vanilloid receptor homologues
JPH11332571A (en) * 1998-05-29 1999-12-07 Taisho Pharmaceut Co Ltd New gene and protein encoded by the same
CA2328895A1 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000037643A2 (en) * 1998-12-23 2000-06-29 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000008145A2 (en) * 1998-08-03 2000-02-17 Novartis Ag Novel genes in control of hematopoiesis
US6451558B1 (en) 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6906178B2 (en) 1998-08-11 2005-06-14 Human Genome Sciences, Inc. Vanilloid receptor-2
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1107797A4 (en) * 1998-08-27 2002-10-16 Quark Biotech Inc Hypoxia regulated genes
US20030163845A1 (en) 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
US6677145B2 (en) 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
JP4486187B2 (en) 1998-10-27 2010-06-23 武田薬品工業株式会社 Novel G protein-coupled receptor protein, its DNA and its ligand
CA2348479A1 (en) * 1998-11-13 2000-05-25 Millennium Pharmaceuticals, Inc. Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof
US7063951B1 (en) 1998-11-13 2006-06-20 Millennium Pharmaceuticals, Inc. Members of the capsaicin/vanilloid receptor family of proteins and uses thereof
ATE346913T1 (en) * 1998-12-04 2006-12-15 Glycozym Aps UDP-N-ACETYL GLUCOSAMINE: GALACTOSE-BATEL, 3-N-ACETYL GALACTOSAMINE-ALPHA-R/ N-ACETYL GLUCOSAMINE-BETAL, 3-N-ACETYL GALACTOSAMINE-ALPHA-R (GLCNAC TO GALNAC) BETAL, 6-N- ACETYL GLUCOSAMINYL TRANSFERASE, C2/4GNT
JP2002540763A (en) * 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 33 human secreted proteins
AU3871300A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
WO2000058494A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
JP2003501009A (en) * 1999-04-09 2003-01-14 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 49 human secreted proteins
DE19919225A1 (en) * 1999-04-28 2000-11-16 Boehringer Ingelheim Int Tumor Associated Antigen
CN1244584A (en) * 1999-05-14 2000-02-16 北京医科大学 Chemotarix factor with immunocyte chemotaxis and hemopoinesis stimulating activity
WO2000071581A1 (en) * 1999-05-20 2000-11-30 Takeda Chemical Industries, Ltd. Novel polypeptide
ATE478145T1 (en) * 1999-06-02 2010-09-15 Genentech Inc SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS CODING THEREFOR
EP1185543A4 (en) * 1999-06-11 2003-09-03 Human Genome Sciences Inc 50 human secreted proteins
AU6181200A (en) * 1999-07-29 2001-02-19 Helix Research Institute Stomach cancer-associated gene
WO2001014552A1 (en) * 1999-08-19 2001-03-01 Kurokawa, Kiyoshi Meg-1 protein
US7070970B2 (en) 1999-08-23 2006-07-04 Abbott Laboratories Elongase genes and uses thereof
DE60032201T2 (en) 1999-09-02 2007-09-20 Leadd B.V. Apoptin binding protein
FR2801056B1 (en) * 1999-11-12 2003-03-28 Commissariat Energie Atomique PROTEIN PRESENT ON THE SURFACE OF HEMATOPOIETIC STEM CELLS OF THE LYMPHOID LINE AND NK CELLS, AND ITS APPLICATIONS
EP1111045A3 (en) * 1999-12-10 2001-09-19 Leadd B.V. Apoptin-associating protein
US7256274B2 (en) 1999-12-10 2007-08-14 Leadd B.V. Apoptin-associating protein
KR20020065510A (en) 1999-12-17 2002-08-13 다케다 야쿠힌 고교 가부시키가이샤 PROCESS FOR PRODUCING KiSS-1 PEPTIDE
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
US7108977B2 (en) * 2000-05-19 2006-09-19 Hoffmann-La Roche Inc. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
AU2001280987A1 (en) * 2000-08-03 2002-02-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of head and neck cancer
AU2002216610A1 (en) * 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002219046A1 (en) * 2000-10-24 2002-05-06 Bayer Aktiengesellschaft Regulation of human ceruloplasmin-like protein
US20020072488A1 (en) * 2000-12-12 2002-06-13 Merkulov Gennady V. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
FR2841261B1 (en) * 2002-06-25 2004-08-27 Univ Pasteur COMPOSITIONS AND METHODS FOR DETECTING PATHOLOGIES AFFECTING NEUROMUSCULAR TRANSMISSION
CN1761680A (en) 2002-12-26 2006-04-19 武田药品工业株式会社 Metastin derivative and use thereof
CA2518541C (en) 2003-03-12 2013-05-21 Takeda Pharmaceutical Company Limited Gonadal function improving agents
WO2004087752A2 (en) * 2003-04-04 2004-10-14 Ingenium Pharmaceuticals Ag Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (en) 2005-12-22 2013-02-21 Takeda Pharmaceutical Metastin derivatives and use thereof
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (en) 2012-02-15 2017-11-02 Novo Nordisk A/S Antibodies that bind to and block a trigger receptor expressed in myeloid cells 1 (TREM-1)
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US20160184454A1 (en) * 2013-01-11 2016-06-30 Asa Abeliovich Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk
KR20240029114A (en) 2014-07-17 2024-03-05 노보 노르디스크 에이/에스 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
AR117566A1 (en) 2018-04-02 2021-08-18 Bristol Myers Squibb Co ANTI-TREM-1 ANTIBODIES AND THEIR USES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
EP0679716A4 (en) * 1993-11-12 1999-06-09 Kenichi Matsubara Gene signature.
PT871702E (en) * 1994-12-06 2005-10-31 Immunex Corp DESIGNATED CYTOKIN LERK-7
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins

Also Published As

Publication number Publication date
WO1998039448A2 (en) 1998-09-11
WO1998039448A3 (en) 1998-11-26
WO1998039448A9 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
CA2283299A1 (en) 186 human secreted proteins
Ho et al. Mammalian initiator apoptotic caspases
Barrow et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice
US6420526B1 (en) 186 human secreted proteins
US6342581B1 (en) Secreted protein HLHFP03
US6703221B1 (en) Notch receptor ligands and uses thereof
CA2339301A1 (en) Hdpbo81 nucleic acids and polypeptides
US20070154912A1 (en) 87 Human Secreted Proteins
JP5554925B2 (en) Translocation and mutant ROS kinase in human non-small cell lung cancer
JP2001524814A (en) 28 human secreted proteins
CA2331154A1 (en) Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
CA2399727A1 (en) Narc-1, subtilase-like homologs
CA2311283A1 (en) Purification and microsequencing of hyaluronidase isozymes
CA2294526A1 (en) 86 human secreted proteins
CA2308768A1 (en) 125 human secreted proteins
CA2372926A1 (en) 143 human secreted proteins
CA2307320A1 (en) 148 human secreted proteins
Lühn et al. Identification and molecular cloning of a functional GDP-fucose transporter in Drosophila melanogaster
US7417124B2 (en) Antibodies specific for phosphorylation sites and screening methods using the same antibodies
CA2298852A1 (en) 83 human secreted proteins
Yin et al. Identification of a novel splice variant of X-linked inhibitor of apoptosis-associated factor 1
KR102458904B1 (en) A Novel Gain-of-Function Mutation in the BMPR2 Gene and Uses Thereof
US20040115682A1 (en) Novel scavenger receptor class a protein
Kovács CHARACTERIZATION OF PEROXIDASIN AND PEROXIDASIN-LIKE PROTEINS IN MAMMALIAN CELLS
Segade et al. Identification of a matrix binding domain in the microfibril-associated glycoproteins 1 and 2 (MAGP1 and 2) and intracellular localization of alternative splice forms

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead